{
  "meta": {
    "id": "test135",
    "title": "Mid Day Module (Pharma-3) - 2024-11-28",
    "category": "Subject Wise / Mixed"
  },
  "questions": [
    {
      "text": "All the following drugs are used for treatment of congestive heart failure except:",
      "options": [
        {
          "label": "A",
          "text": "Nesiritide",
          "correct": false
        },
        {
          "label": "B",
          "text": "Sacubitril",
          "correct": false
        },
        {
          "label": "C",
          "text": "Trimetazidine",
          "correct": true
        },
        {
          "label": "D",
          "text": "Metoprolol",
          "correct": false
        }
      ],
      "correct_answer": "C. Trimetazidine",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/08/screenshot-2024-05-08-094413.png"
      ],
      "explanation": "<p><strong>Ans. C) Trimetazidine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Nesiritide: Nesiritide is a recombinant B-type natriuretic peptide that has vasodilatory effects and is used in the management of acute decompensated heart failure.</li><li>\u2022 Option A. Nesiritide:</li><li>\u2022 recombinant B-type natriuretic peptide</li><li>\u2022 vasodilatory effects</li><li>\u2022 acute decompensated heart failure.</li><li>\u2022 Option B. Sacubitril: When combined with valsartan (a neprilysin inhibitor and an angiotensin II receptor blocker, respectively), sacubitril is used to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure.</li><li>\u2022 Option B. Sacubitril:</li><li>\u2022 combined with valsartan</li><li>\u2022 neprilysin inhibitor and an angiotensin II receptor blocker,</li><li>\u2022 reduce the risk of cardiovascular death</li><li>\u2022 hospitalization for heart failure in patients</li><li>\u2022 chronic heart</li><li>\u2022 failure.</li><li>\u2022 Option D. Metoprolol: Metoprolol is a beta-blocker that is used in the management of CHF. It reduces myocardial oxygen demand and can improve survival in patients with heart failure.</li><li>\u2022 Option D. Metoprolol:</li><li>\u2022 beta-blocker</li><li>\u2022 CHF.</li><li>\u2022 reduces myocardial oxygen demand</li><li>\u2022 improve survival in patients with heart failure.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "76a0acca",
      "audio": ""
    },
    {
      "text": "Angiotensin receptor blocker which blocks thromboxane A2 receptor is?",
      "options": [
        {
          "label": "A",
          "text": "Losartan",
          "correct": true
        },
        {
          "label": "B",
          "text": "Telmisartan",
          "correct": false
        },
        {
          "label": "C",
          "text": "Candesartan",
          "correct": false
        },
        {
          "label": "D",
          "text": "Olmesartan",
          "correct": false
        }
      ],
      "correct_answer": "A. Losartan",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Losartan</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Telmisartan: Incorrect because Telmisartan is known as a partial agonist of peroxisome proliferator-activated receptor gamma (PPAR-\u03b3), which differentiates it from Losartan and does not confer the ability to block the thromboxane A2 receptor.</li><li>\u2022 Option B. Telmisartan:</li><li>\u2022 Incorrect</li><li>\u2022 Telmisartan is known as a partial agonist of peroxisome proliferator-activated receptor</li><li>\u2022 gamma (PPAR-\u03b3),</li><li>\u2022 does not</li><li>\u2022 block the thromboxane A2 receptor.</li><li>\u2022 Option C. Candesartan: Incorrect as Candesartan is an inactive ester prodrug that does not possess the ability to block the thromboxane A2 receptor. It is hydrolyzed to its active form within the body, which acts selectively on the angiotensin receptor.</li><li>\u2022 Option C. Candesartan:</li><li>\u2022 Incorrect</li><li>\u2022 Candesartan</li><li>\u2022 inactive ester</li><li>\u2022 does not</li><li>\u2022 block the</li><li>\u2022 thromboxane A2 receptor.</li><li>\u2022 hydrolyzed</li><li>\u2022 its active form</li><li>\u2022 acts selectively</li><li>\u2022 angiotensin receptor.</li><li>\u2022 Option D. Olmesartan: Incorrect for this question since Olmesartan, while also being an inactive ester prodrug hydrolyzed to its active form , does not block the thromboxane A2 receptor. It is cleared by renal elimination and biliary excretion and does not require dose adjustment in patients with mild-to-moderate renal or hepatic impairment.</li><li>\u2022 Option D. Olmesartan:</li><li>\u2022 Incorrect</li><li>\u2022 Olmesartan,</li><li>\u2022 inactive ester prodrug hydrolyzed</li><li>\u2022 active form</li><li>\u2022 does not block the thromboxane A2 receptor.</li><li>\u2022 cleared by renal elimination</li><li>\u2022 biliary excretion</li><li>\u2022 does not</li><li>\u2022 mild-to-moderate renal or hepatic impairment.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Losartan is unique among angiotensin receptor blockers in that it also competitively antagonizes the thromboxane A2 receptor, contributing to its antiplatelet effects.</li><li>\u2022 Losartan</li><li>\u2022 angiotensin receptor blockers</li><li>\u2022 competitively antagonizes</li><li>\u2022 thromboxane A2 receptor,</li><li>\u2022 antiplatelet effects.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b776e021",
      "audio": ""
    },
    {
      "text": "A patient is taking atorvastatin for dyslipidemia. Which of these drugs should be avoided in this patient?",
      "options": [
        {
          "label": "A",
          "text": "Clarithromycin",
          "correct": true
        },
        {
          "label": "B",
          "text": "Oxycodone",
          "correct": false
        },
        {
          "label": "C",
          "text": "Rivaroxaban",
          "correct": false
        },
        {
          "label": "D",
          "text": "Adalimumab",
          "correct": false
        }
      ],
      "correct_answer": "A. Clarithromycin",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Clarithromycin</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Oxycodone: Incorrect because oxycodone, an opioid analgesic, does not significantly interact with the CYP3A4 enzyme in a way that would affect the metabolism of atorvastatin to a clinically relevant extent.</li><li>\u2022 Option B. Oxycodone:</li><li>\u2022 Incorrect</li><li>\u2022 opioid analgesic,</li><li>\u2022 does not</li><li>\u2022 CYP3A4 enzyme</li><li>\u2022 metabolism of atorvastatin to a clinically relevant extent.</li><li>\u2022 Option C. Rivaroxaban: Incorrect as rivaroxaban, an anticoagulant , is not metabolized by CYP3A4 in a way that would interfere with atorvastatin metabolism.</li><li>\u2022 Option C. Rivaroxaban:</li><li>\u2022 Incorrect</li><li>\u2022 rivaroxaban,</li><li>\u2022 anticoagulant</li><li>\u2022 not metabolized by CYP3A4</li><li>\u2022 atorvastatin metabolism.</li><li>\u2022 Option D. Adalimumab: Incorrect because adalimumab , an immunosuppressive drug used to treat autoimmune diseases, does not interact with the CYP3A4 enzyme and thus would not affect atorvastatin levels.</li><li>\u2022 Option D. Adalimumab:</li><li>\u2022 Incorrect</li><li>\u2022 adalimumab</li><li>\u2022 immunosuppressive drug</li><li>\u2022 autoimmune diseases, does not</li><li>\u2022 CYP3A4 enzyme</li><li>\u2022 would not</li><li>\u2022 atorvastatin levels.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 When prescribing statins, avoid concomitant use with drugs that inhibit CYP3A4, such as clarithromycin, to prevent an increase in their plasma levels which could lead to myopathy. Other notable CYP3A4 inhibitors to avoid include amiodarone, gemfibrozil, HIV protease inhibitors (such as saquinavir, ritonavir), and itraconazole.</li><li>\u2022 statins,</li><li>\u2022 avoid</li><li>\u2022 inhibit CYP3A4,</li><li>\u2022 clarithromycin,</li><li>\u2022 increase</li><li>\u2022 plasma levels</li><li>\u2022 lead to myopathy.</li><li>\u2022 CYP3A4 inhibitors</li><li>\u2022 amiodarone, gemfibrozil, HIV</li><li>\u2022 protease inhibitors (such as saquinavir, ritonavir), and itraconazole.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c5cc6a89",
      "audio": ""
    },
    {
      "text": "Which of the following statement is True regarding Sacubitril?",
      "options": [
        {
          "label": "A",
          "text": "It is a drug that can act by inhibiting angiotensin converting enzyme",
          "correct": false
        },
        {
          "label": "B",
          "text": "It is a drug used in combination with valsartan for congestive heart failure",
          "correct": true
        },
        {
          "label": "C",
          "text": "Hypokalemia is an adverse effect of sacubitril",
          "correct": false
        },
        {
          "label": "D",
          "text": "Sacubitril is combined with ramipril for treatment of hypertension",
          "correct": false
        }
      ],
      "correct_answer": "B. It is a drug used in combination with valsartan for congestive heart failure",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) It is a drug used in combination with valsartan for congestive heart failure</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Incorrect because sacubitril is not an angiotensin converting enzyme (ACE) inhibitor , which typically have names ending in -pril.</li><li>\u2022 Option A.</li><li>\u2022 Incorrect</li><li>\u2022 sacubitril is not an angiotensin converting enzyme (ACE) inhibitor</li><li>\u2022 Option C. Incorrect as hypokalemia is not a side effect associated with sacubitril. It is more commonly associated with traditional diuretics rather than neprilysin inhibitors.</li><li>\u2022 Option C.</li><li>\u2022 Incorrect</li><li>\u2022 hypokalemia</li><li>\u2022 not a side effect</li><li>\u2022 sacubitril.</li><li>\u2022 more</li><li>\u2022 traditional</li><li>\u2022 diuretics</li><li>\u2022 neprilysin inhibitors.</li><li>\u2022 Option D. Incorrect because sacubitril is combined with valsartan, not ramipril , and the combination is used for heart failure, not specifically for hypertension.</li><li>\u2022 Option D.</li><li>\u2022 Incorrect</li><li>\u2022 sacubitril is combined with valsartan, not ramipril</li><li>\u2022 heart failure,</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Sacubitril is a neprilysin inhibitor used in combination with valsartan as an ARNI for the treatment of heart failure to reduce the risk of cardiovascular death and heart failure hospitalization , particularly in patients with reduced ejection fraction.</li><li>\u2022 Sacubitril is a neprilysin inhibitor</li><li>\u2022 with valsartan</li><li>\u2022 ARNI for the treatment of heart failure</li><li>\u2022 reduce the risk</li><li>\u2022 cardiovascular death and heart failure hospitalization</li><li>\u2022 reduced ejection fraction.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "cdbbee94",
      "audio": ""
    },
    {
      "text": "Which of the following is the drug of choice for digoxin induced ventricular tachyarrhythmias?",
      "options": [
        {
          "label": "A",
          "text": "Quinidine",
          "correct": false
        },
        {
          "label": "B",
          "text": "Amiodarone",
          "correct": false
        },
        {
          "label": "C",
          "text": "Lignocaine",
          "correct": true
        },
        {
          "label": "D",
          "text": "Phenytoin",
          "correct": false
        }
      ],
      "correct_answer": "C. Lignocaine",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Lignocaine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Quinidine: Quinidine is an antiarrhythmic that can increase serum digoxin levels and is contraindicated in digoxin-induced arrhythmias because it may exacerbate toxicity.</li><li>\u2022 Option A. Quinidine:</li><li>\u2022 antiarrhythmic</li><li>\u2022 increase serum digoxin levels</li><li>\u2022 contraindicated in digoxin-induced arrhythmias</li><li>\u2022 exacerbate toxicity.</li><li>\u2022 Option B. Amiodarone: While amiodarone is a versatile antiarrhythmic agent used in various types of arrhythmias , it can interact with digoxin and increase its levels , potentially worsening toxicity.</li><li>\u2022 Option B. Amiodarone:</li><li>\u2022 versatile antiarrhythmic agent</li><li>\u2022 various types of arrhythmias</li><li>\u2022 interact</li><li>\u2022 digoxin and increase its levels</li><li>\u2022 worsening toxicity.</li><li>\u2022 Option D. Phenytoin: Phenytoin is effective for ventricular arrhythmias, especially in the context of acute myocardial infarction, but it is not the first choice for digoxin-induced arrhythmias. It can be used if lignocaine is not available or contraindicated.</li><li>\u2022 Option D. Phenytoin:</li><li>\u2022 ventricular arrhythmias,</li><li>\u2022 acute myocardial infarction,</li><li>\u2022 not the first choice for digoxin-induced arrhythmias.</li><li>\u2022 can be used</li><li>\u2022 lignocaine is not available or contraindicated.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The educational goal is to understand the appropriate management of digoxin-induced ventricular tachyarrhythmias . Recognizing lignocaine as the drug of choice in this scenario is critical for effectively addressing the cardiac toxicity associated with digoxin overdose , minimizing the risk of further cardiac complications.</li><li>\u27a4 appropriate management of digoxin-induced ventricular tachyarrhythmias</li><li>\u27a4 lignocaine</li><li>\u27a4 drug of choice</li><li>\u27a4 critical for effectively addressing the cardiac toxicity</li><li>\u27a4 digoxin</li><li>\u27a4 overdose</li><li>\u27a4 minimizing the risk</li><li>\u27a4 cardiac complications.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "3f8d9f12",
      "audio": ""
    },
    {
      "text": "Which of the following drug is used in CHF for relief of congestive symptoms and restoration of cardiac performance but does not possess inotropic action?",
      "options": [
        {
          "label": "A",
          "text": "Digoxin",
          "correct": false
        },
        {
          "label": "B",
          "text": "Dobutamine",
          "correct": false
        },
        {
          "label": "C",
          "text": "Amrinone",
          "correct": false
        },
        {
          "label": "D",
          "text": "Metoprolol",
          "correct": true
        }
      ],
      "correct_answer": "D. Metoprolol",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Metoprolol</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Digoxin: Digoxin has a positive inotropic effect , increasing the force of cardiac contractions , and is used in CHF to improve symptoms and cardiac performance. It does not fit the criteria as it possesses inotropic action.</li><li>\u2022 Option A. Digoxin:</li><li>\u2022 positive inotropic effect</li><li>\u2022 increasing the force of cardiac contractions</li><li>\u2022 CHF to improve</li><li>\u2022 symptoms and cardiac performance.</li><li>\u2022 does not</li><li>\u2022 inotropic action.</li><li>\u2022 Option B. Dobutamine: Dobutamine is a beta-1 adrenergic agonist with positive inotropic effects , used primarily in acute heart failure to increase cardiac output. It directly increases the force of heart contractions.</li><li>\u2022 Option B. Dobutamine:</li><li>\u2022 beta-1 adrenergic agonist</li><li>\u2022 positive inotropic effects</li><li>\u2022 acute heart</li><li>\u2022 failure</li><li>\u2022 increase cardiac output.</li><li>\u2022 increases the force of heart contractions.</li><li>\u2022 Option C. Amrinone: Amrinone is a phosphodiesterase inhibitor with positive inotropic and vasodilatory effects , used to improve cardiac output in heart failure patients. Like dobutamine and digoxin, it increases the force of cardiac contractions.</li><li>\u2022 Option C. Amrinone:</li><li>\u2022 phosphodiesterase inhibitor</li><li>\u2022 positive inotropic and vasodilatory effects</li><li>\u2022 improve</li><li>\u2022 cardiac output</li><li>\u2022 dobutamine and digoxin,</li><li>\u2022 increases the force of cardiac contractions.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The educational goal is to understand the role of different classes of drugs in the management of CHF, particularly distinguishing those with and without inotropic action. Metoprolol's use in CHF illustrates the importance of managing heart rate and reducing myocardial oxygen demand as part of a strategy to improve cardiac performance without directly increasing the force of contraction</li><li>\u27a4 different classes of drugs</li><li>\u27a4 CHF,</li><li>\u27a4 distinguishing</li><li>\u27a4 with and without inotropic action.</li><li>\u27a4 Metoprolol's</li><li>\u27a4 CHF illustrates</li><li>\u27a4 heart rate and reducing</li><li>\u27a4 myocardial oxygen demand</li><li>\u27a4 improve cardiac performance</li><li>\u27a4 without directly increasing the force of contraction</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "5e41d04e",
      "audio": ""
    },
    {
      "text": "All the following are adverse effects of amiodarone except:",
      "options": [
        {
          "label": "A",
          "text": "Pulmonary fibrosis",
          "correct": false
        },
        {
          "label": "B",
          "text": "Corneal microdeposits",
          "correct": false
        },
        {
          "label": "C",
          "text": "Photosensitivity",
          "correct": false
        },
        {
          "label": "D",
          "text": "Tachycardia",
          "correct": true
        }
      ],
      "correct_answer": "D. Tachycardia",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Tachycardia</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Pulmonary fibrosis: This is a serious and well-recognized side effect of amiodarone, especially with long-term use.</li><li>\u2022 Option A. Pulmonary fibrosis:</li><li>\u2022 serious and well-recognized side effect of amiodarone,</li><li>\u2022 long-term use.</li><li>\u2022 Option B. Corneal microdeposits: Common and typically reversible upon discontinuation of the drug.</li><li>\u2022 Option B. Corneal microdeposits:</li><li>\u2022 Common</li><li>\u2022 reversible upon discontinuation of the drug.</li><li>\u2022 Option C. Photosensitivity: This adverse effect can occur in patients taking amiodarone , leading to increased risk of sunburn and skin pigmentation.</li><li>\u2022 Option C. Photosensitivity:</li><li>\u2022 adverse effect</li><li>\u2022 , leading to increased risk of sunburn and skin</li><li>\u2022 pigmentation.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Amiodarone is a class III anti-arrhythmic drug associated with several adverse effects including pulmonary fibrosis, corneal microdeposits, and photosensitivity, but not tachycardia; in fact, it more commonly causes bradycardia.</li><li>\u2022 Amiodarone</li><li>\u2022 class III anti-arrhythmic drug</li><li>\u2022 several adverse effects</li><li>\u2022 pulmonary fibrosis, corneal</li><li>\u2022 microdeposits, and photosensitivity,</li><li>\u2022 in fact, it more commonly causes bradycardia.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "d6714317",
      "audio": ""
    },
    {
      "text": "A new antiarrhythmic drug is found to be effective against both atrial and ventricular arrhythmias. Its effect on action potential is shown in the Figure. The effect of this new drug is most like:",
      "options": [
        {
          "label": "A",
          "text": "Lignocaine",
          "correct": false
        },
        {
          "label": "B",
          "text": "Propanolol",
          "correct": false
        },
        {
          "label": "C",
          "text": "Encainide",
          "correct": false
        },
        {
          "label": "D",
          "text": "Quinidine",
          "correct": true
        }
      ],
      "correct_answer": "D. Quinidine",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/25/image-2-min.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Quinidine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Lignocaine: Lignocaine (Lidocaine) is a Class IB antiarrhythmic drug that primarily works by shortening the action potential duration by blocking sodium channels , particularly in ischemic or depolarized cells . It does not prolong the action potential plateau.</li><li>\u2022 Option A. Lignocaine:</li><li>\u2022 Class IB antiarrhythmic drug</li><li>\u2022 shortening the action potential</li><li>\u2022 blocking sodium channels</li><li>\u2022 ischemic or depolarized cells</li><li>\u2022 does not</li><li>\u2022 action</li><li>\u2022 potential plateau.</li><li>\u2022 Option B. Propranolol: Propranolol is a Class II antiarrhythmic , which is a beta-blocker that reduces sympathetic nervous system activity. It does not have a direct effect on the action potential duration or plateau phase.</li><li>\u2022 Option B. Propranolol:</li><li>\u2022 Class II antiarrhythmic</li><li>\u2022 beta-blocker</li><li>\u2022 sympathetic nervous system</li><li>\u2022 activity.</li><li>\u2022 does not</li><li>\u2022 action potential duration or plateau phase.</li><li>\u2022 Option C. Encainide: Encainide , which is no longer widely used, was a Class IC antiarrhythmic drug that significantly slows conduction by blocking sodium channels but does not typically prolong the action potential duration.</li><li>\u2022 Option C. Encainide:</li><li>\u2022 Encainide</li><li>\u2022 no longer widely used,</li><li>\u2022 Class IC antiarrhythmic drug</li><li>\u2022 blocking sodium channels</li><li>\u2022 does not</li><li>\u2022 action potential duration.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The educational goal is to recognize the electrophysiologic effects of antiarrhythmic drugs on the cardiac action potential. Understanding how these drugs affect the action potential can provide insights into their therapeutic uses and potential arrhythmogenic risks. Quinidine's effect of prolonging the action potential duration is useful in the treatment of both atrial and ventricular arrhythmias, but it also carries the risk of proarrhythmia, underlining the need for careful patient selection and monitoring.</li><li>\u27a4 electrophysiologic effects of antiarrhythmic drugs</li><li>\u27a4 action potential</li><li>\u27a4 therapeutic uses and potential</li><li>\u27a4 arrhythmogenic risks. Quinidine's</li><li>\u27a4 prolonging the action potential duration</li><li>\u27a4 both atrial and</li><li>\u27a4 ventricular arrhythmias,</li><li>\u27a4 risk of proarrhythmia,</li><li>\u27a4 careful patient selection</li><li>\u27a4 monitoring.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "9137afb0",
      "audio": ""
    },
    {
      "text": "Trimetazidine is a drug approved for the treatment of angina pectoris. Its mechanism of action is assumed to be:",
      "options": [
        {
          "label": "A",
          "text": "Bradycardiac agent",
          "correct": false
        },
        {
          "label": "B",
          "text": "Rho kinase inhibition",
          "correct": false
        },
        {
          "label": "C",
          "text": "K channel opener",
          "correct": false
        },
        {
          "label": "D",
          "text": "Inhibiting mitochondrial LC3- KAT",
          "correct": true
        }
      ],
      "correct_answer": "D. Inhibiting mitochondrial LC3- KAT",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Inhibiting mitochondrial LC3-KAT</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Incorrect because ivabradine is the bradycardiac agent used for angina , which acts by blocking the funny current in the SA node , not trimetazidine.</li><li>\u2022 Option A.</li><li>\u2022 Incorrect</li><li>\u2022 ivabradine is the bradycardiac agent</li><li>\u2022 for angina</li><li>\u2022 acts by blocking the funny current in the SA</li><li>\u2022 node</li><li>\u2022 Option B. Incorrect as fasudil is the rho kinase inhibitor utilized for angina pectoris , not trimetazidine.</li><li>\u2022 Option B.</li><li>\u2022 Incorrect</li><li>\u2022 fasudil</li><li>\u2022 rho kinase inhibitor utilized for angina pectoris</li><li>\u2022 Option C. Incorrect because nicorandil is the K channel opener (which also has nitric oxide releasing properties ) that is used for angina pectoris, rather than trimetazidine.</li><li>\u2022 Option C.</li><li>\u2022 Incorrect</li><li>\u2022 nicorandil is the K channel opener</li><li>\u2022 nitric oxide releasing properties</li><li>\u2022 used for</li><li>\u2022 angina pectoris,</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Trimetazidine is an antianginal medication that reduces the frequency of angina attacks and increases exercise capacity through a mechanism that likely involves the inhibition of mitochondrial LC3-KAT, leading to a shift from fatty acid to glucose metabolism in the myocardium and resulting in a reduced oxygen demand.</li><li>\u2022 Trimetazidine</li><li>\u2022 antianginal medication</li><li>\u2022 reduces the frequency of angina attacks</li><li>\u2022 increases exercise capacity</li><li>\u2022 inhibition of mitochondrial LC3-KAT,</li><li>\u2022 fatty acid to glucose metabolism</li><li>\u2022 myocardium and resulting</li><li>\u2022 reduced oxygen demand.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "29ec0e37",
      "audio": ""
    },
    {
      "text": "All the following statements about nesiritide are true except?",
      "options": [
        {
          "label": "A",
          "text": "It is a BNP analogue",
          "correct": false
        },
        {
          "label": "B",
          "text": "It can be used in decompensated CHF",
          "correct": false
        },
        {
          "label": "C",
          "text": "It can be administered orally",
          "correct": true
        },
        {
          "label": "D",
          "text": "It causes loss of Na + in the urine",
          "correct": false
        }
      ],
      "correct_answer": "C. It can be administered orally",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) It can be administered orally</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. It is a BNP analogue: This statement is true. Nesiritide is a synthetic version of BNP that is used in the management of acute decompensated heart failure.</li><li>\u2022 Option A. It is a BNP analogue:</li><li>\u2022 true. Nesiritide</li><li>\u2022 synthetic</li><li>\u2022 BNP</li><li>\u2022 acute decompensated heart failure.</li><li>\u2022 Option B. It can be used in decompensated CHF: This statement is true . Nesiritide is indicated for the treatment of acute decompensated congestive heart failure (CHF), where it works by causing vasodilation and natriuresis.</li><li>\u2022 Option B. It can be used in decompensated CHF:</li><li>\u2022 true</li><li>\u2022 Nesiritide</li><li>\u2022 treatment of acute</li><li>\u2022 decompensated congestive heart failure (CHF),</li><li>\u2022 vasodilation and natriuresis.</li><li>\u2022 Option D. It causes loss of Na+ in the urine: This statement is true . Nesiritide promotes natriuresis, which is the excretion of sodium in the urine , contributing to its beneficial effects in heart failure.</li><li>\u2022 Option D. It causes loss of Na+ in the urine:</li><li>\u2022 true</li><li>\u2022 natriuresis,</li><li>\u2022 excretion of sodium</li><li>\u2022 urine</li><li>\u2022 beneficial effects in heart failure.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The educational goal is to understand the administration and effects of nesiritide in the treatment of acute decompensated heart failure . Nesiritide must be administered intravenously due to its peptide nature and the gastrointestinal degradation of oral peptides</li><li>\u27a4 administration and effects of nesiritide</li><li>\u27a4 acute decompensated heart</li><li>\u27a4 failure</li><li>\u27a4 administered intravenously</li><li>\u27a4 peptide</li><li>\u27a4 gastrointestinal degradation of oral peptides</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ff7e7130",
      "audio": ""
    },
    {
      "text": "Sodium nitroprusside acts by stimulation of?",
      "options": [
        {
          "label": "A",
          "text": "Guanylyl cyclase",
          "correct": true
        },
        {
          "label": "B",
          "text": "Phosphokinase 1,2",
          "correct": false
        },
        {
          "label": "C",
          "text": "Phospholipase A",
          "correct": false
        },
        {
          "label": "D",
          "text": "Phospholipase B",
          "correct": false
        }
      ],
      "correct_answer": "A. Guanylyl cyclase",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Guanylyl cyclase</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Phosphokinase 1,2: There is no enzyme specifically named phosphokinase 1,2. This option does not relate to the known mechanism of action of sodium nitroprusside.</li><li>\u2022 Option B. Phosphokinase 1,2:</li><li>\u2022 no</li><li>\u2022 phosphokinase 1,2.</li><li>\u2022 does not</li><li>\u2022 Option C. Phospholipase A: Phospholipase A is an enzyme that hydrolyzes phospholipids to produce fatty acids and lysophospholipids . It is not directly involved in the mechanism of action of sodium nitroprusside.</li><li>\u2022 Option C. Phospholipase A:</li><li>\u2022 Phospholipase A is an enzyme</li><li>\u2022 hydrolyzes phospholipids</li><li>\u2022 fatty acids</li><li>\u2022 lysophospholipids</li><li>\u2022 not</li><li>\u2022 mechanism of action of sodium nitroprusside.</li><li>\u2022 Option D. Phospholipase B: Phospholipase B also acts on phospholipids but is not related to the vasodilatory action of sodium nitroprusside.</li><li>\u2022 Option D. Phospholipase B:</li><li>\u2022 acts on phospholipids</li><li>\u2022 not</li><li>\u2022 vasodilatory action of sodium</li><li>\u2022 nitroprusside.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The educational goal is to understand the pharmacodynamics of sodium nitroprusside , a potent vasodilator. By knowing that its mechanism involves th e stimulation of guanylyl cyclase and the subsequent increase in cGMP, healthcare professionals can better anticipate its effects and necessary precautions, such as monitoring for signs of cyanide toxicity due to its metabolism. Understanding the differences in mechanisms among various vasodilators is crucial for selecting the appropriate agent in clinical scenarios.</li><li>\u27a4 pharmacodynamics of sodium nitroprusside</li><li>\u27a4 potent vasodilator.</li><li>\u27a4 e stimulation of guanylyl cyclase</li><li>\u27a4 increase in cGMP,</li><li>\u27a4 monitoring for signs of cyanide toxicity</li><li>\u27a4 differences in mechanisms</li><li>\u27a4 vasodilators</li><li>\u27a4 selecting the appropriate agent</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "95f8841e",
      "audio": ""
    },
    {
      "text": "Which of the following medications has been shown to reduce mortality in heart failure with reduced ejection fraction?",
      "options": [
        {
          "label": "A",
          "text": "Digoxin",
          "correct": false
        },
        {
          "label": "B",
          "text": "Furosemide",
          "correct": false
        },
        {
          "label": "C",
          "text": "Metoprolol succinate",
          "correct": true
        },
        {
          "label": "D",
          "text": "Dobutamine",
          "correct": false
        }
      ],
      "correct_answer": "C. Metoprolol succinate",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Metoprolol succinate</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Digoxin: While digoxin can improve symptoms and reduce hospitalizations by increasing the force of cardiac c ontractions and controlling heart rate in patients with heart failure, it has not been shown to reduce mortality in these patients.</li><li>\u2022 Option A. Digoxin:</li><li>\u2022 improve symptoms and reduce hospitalizations by increasing the force of cardiac c</li><li>\u2022 controlling heart rate</li><li>\u2022 heart failure,</li><li>\u2022 has not been shown to reduce mortality</li><li>\u2022 Option B. Furosemide: Furosemide is a loop diuretic that is used to reduce symptoms of congestion in heart failure by promoting the excretion of sodium and water . However, it does not have a direct effect on reducing mortality in heart failure with reduced ejection fraction.</li><li>\u2022 Option B. Furosemide:</li><li>\u2022 loop diuretic</li><li>\u2022 reduce symptoms of congestion in heart failure</li><li>\u2022 excretion of sodium and water</li><li>\u2022 does not</li><li>\u2022 direct effect on reducing mortality in heart failure</li><li>\u2022 reduced</li><li>\u2022 ejection fraction.</li><li>\u2022 Option D. Dobutamine: Dobutamine is a beta-1 agonist used in acute heart failure to increase cardiac output . It is generally used for short-term support in hospitalized patients and is not shown to reduce long-term mortality in chronic heart failure ; its long-term use can actually be harmful due to increased cardiac oxygen demand and potential for arrhythmia.</li><li>\u2022 Option D. Dobutamine:</li><li>\u2022 beta-1 agonist</li><li>\u2022 acute heart failure to increase cardiac output</li><li>\u2022 short-term support in hospitalized patients</li><li>\u2022 not</li><li>\u2022 reduce long-term mortality in chronic heart failure</li><li>\u2022 harmful due to increased cardiac oxygen demand</li><li>\u2022 arrhythmia.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The educational goal is to understand the role of different classes of drugs in the treatment of heart failure with reduced ejection fraction, particularly those that have been demonstrated to reduce mortality.</li><li>\u27a4 different classes of drugs</li><li>\u27a4 heart failure</li><li>\u27a4 reduced ejection</li><li>\u27a4 fraction,</li><li>\u27a4 have been demonstrated to reduce mortality.</li><li>\u27a4 Drugs reducing mortality in CHF include:</li><li>\u27a4 Drugs reducing mortality in CHF include:</li><li>\u27a4 Beta blockers ACE inhibitors ARBs Aldosterone antagonists Ivabradine Hydralazine + Isosorbide dinitrate</li><li>\u27a4 Beta blockers</li><li>\u27a4 ACE inhibitors</li><li>\u27a4 ARBs</li><li>\u27a4 Aldosterone antagonists</li><li>\u27a4 Ivabradine</li><li>\u27a4 Hydralazine + Isosorbide dinitrate</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "36c34edb",
      "audio": ""
    },
    {
      "text": "The primary mechanism of action of nitrates in a patient of classical angina is:",
      "options": [
        {
          "label": "A",
          "text": "Coronary vasodilation",
          "correct": false
        },
        {
          "label": "B",
          "text": "Decrease heart rate",
          "correct": false
        },
        {
          "label": "C",
          "text": "Decreased afterload",
          "correct": false
        },
        {
          "label": "D",
          "text": "Decreases preload",
          "correct": true
        }
      ],
      "correct_answer": "D. Decreases preload",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Decreases preload</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Coronary Vasodilation : Nitrates do cause some coronary vasodilation, but this is not their primary action in treating classical angina. Endothelium independent coronary vasodilation is the primary mechanism of nitrates in treatment of variant angina. In a typical vascular system, the endothelium plays a crucial role in regulating blood vessel tone and blood flow . It does this by releasing substances like nitric oxide (NO), which promote vasodilation. However, nitrates work independently of the endothelial cells. They are converted into nitric oxide (NO) within the smooth muscle cells. This NO then activates an enzyme called guanylate cyclase , which increases the levels of cyclic guanosine monophosphate (cGMP). The increase in cGMP leads to relaxation of the smooth muscle cells , resulting in vasodilatio n. This mechanism is particularly important in conditions like variant angina, where there are episodes of coronary artery spasm . Nitrate s can effectively relax the smooth muscle in the coronary arteries, reducing the spasm and thus alleviating the angina pain . This action is independent of the endothelium, which may not be functioning optimally in all individuals with coronary artery disease.</li><li>\u2022 Option A. Coronary Vasodilation</li><li>\u2022 Nitrates do</li><li>\u2022 coronary vasodilation,</li><li>\u2022 not their primary action</li><li>\u2022 classical angina.</li><li>\u2022 Endothelium independent coronary vasodilation</li><li>\u2022 primary</li><li>\u2022 nitrates</li><li>\u2022 variant</li><li>\u2022 angina.</li><li>\u2022 endothelium</li><li>\u2022 regulating blood vessel tone and blood flow</li><li>\u2022 nitric oxide (NO),</li><li>\u2022 promote vasodilation.</li><li>\u2022 nitrates work independently of the endothelial</li><li>\u2022 cells.</li><li>\u2022 converted into nitric oxide (NO)</li><li>\u2022 within</li><li>\u2022 smooth muscle cells.</li><li>\u2022 NO</li><li>\u2022 guanylate cyclase</li><li>\u2022 increases the levels of cyclic guanosine monophosphate (cGMP).</li><li>\u2022 increase in cGMP</li><li>\u2022 smooth muscle cells</li><li>\u2022 vasodilatio</li><li>\u2022 variant angina,</li><li>\u2022 episodes of coronary artery spasm</li><li>\u2022 Nitrate</li><li>\u2022 relax the smooth muscle</li><li>\u2022 coronary arteries,</li><li>\u2022 reducing the spasm</li><li>\u2022 alleviating the angina pain</li><li>\u2022 independent</li><li>\u2022 endothelium,</li><li>\u2022 not</li><li>\u2022 functioning optimally</li><li>\u2022 coronary artery disease.</li><li>\u2022 Option B. Decrease Heart Rate : Nitrates do not have a significant effect on heart rate. Drugs that primarily decrease heart rate , such as beta-blockers , are used separately for this purpose in the management of angina.</li><li>\u2022 Option B. Decrease Heart Rate</li><li>\u2022 do not</li><li>\u2022 heart rate.</li><li>\u2022 primarily decrease heart rate</li><li>\u2022 beta-blockers</li><li>\u2022 Option C. Decrease Afterload : While nitrates can have a minor effect on afterload due to systemic vasodilation , decreasing afterload is not their primary mechanism of action in treating angina . Medications like ACE inhibitors or angiotensin receptor blockers are more effective for this purpose.</li><li>\u2022 Option C. Decrease Afterload</li><li>\u2022 nitrates</li><li>\u2022 minor effect on afterload</li><li>\u2022 systemic vasodilation</li><li>\u2022 decreasing</li><li>\u2022 afterload</li><li>\u2022 not</li><li>\u2022 treating angina</li><li>\u2022 ACE inhibitors or angiotensin receptor</li><li>\u2022 blockers</li><li>\u2022 more</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 The mechanism of action of nitrates in classical angina is decrease in preload. The mechanism of action of nitrates i n variant angina is endothelium independent coronary vasodilation.</li><li>\u2022 The mechanism of action of nitrates in classical angina is decrease in preload.</li><li>\u2022 mechanism of action of nitrates</li><li>\u2022 classical angina is decrease in preload.</li><li>\u2022 The mechanism of action of nitrates i n variant angina is endothelium independent coronary vasodilation.</li><li>\u2022 mechanism of action of nitrates</li><li>\u2022 n variant angina</li><li>\u2022 endothelium independent coronary vasodilation.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "f27f6d3d",
      "audio": ""
    },
    {
      "text": "A 56-year-old patient with essential hypertension on ACE inhibitors for 6 months developed chronic refractory dry cough. What would be the correct action to be taken?",
      "options": [
        {
          "label": "A",
          "text": "Reduce the dose of ACE inhibitor",
          "correct": false
        },
        {
          "label": "B",
          "text": "Add anti- tussive for treatment of cough",
          "correct": false
        },
        {
          "label": "C",
          "text": "Change to Angiotensin receptor blocker (ARB)",
          "correct": true
        },
        {
          "label": "D",
          "text": "Order for a CT scan of chest",
          "correct": false
        }
      ],
      "correct_answer": "C. Change to Angiotensin receptor blocker (ARB)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Change to Angiotensin receptor blocker (ARB)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Reduce the dose of ACE inhibitor: Reducing the dose of the ACE inhibitor would not alleviate the cough since the adverse effect is not dose-related and the patient has already developed sensitivity to the drug.</li><li>\u2022 Option A. Reduce the dose of ACE inhibitor:</li><li>\u2022 would not alleviate the cough</li><li>\u2022 Option B. Add anti-tussive for the treatment of cough: An anti-tussive would not address the underlying cause of the cough, which in this case is due to the ACE inhibitors.</li><li>\u2022 Option B. Add anti-tussive for the treatment of cough:</li><li>\u2022 would not</li><li>\u2022 cause of the cough,</li><li>\u2022 due to the ACE inhibitors.</li><li>\u2022 Option D. Order for a CT scan of the chest: A CT scan would be an unnecessary investigation and an additional cost burden for the patient, given that the cause of the chronic cough is already known to be drug-related and not indicative of an underlying pulmonary pathology.</li><li>\u2022 Option D. Order for a CT scan of the chest:</li><li>\u2022 unnecessary investigation</li><li>\u2022 chronic cough is already known to be drug-related</li><li>\u2022 not indicative of an underlying</li><li>\u2022 pulmonary pathology.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 For a patient who develops a chronic dry cough while on ACE inhibitors, changing to an Angiotensin receptor blocker (ARB) is the correct course of action, a s ARBs do not cause this side effect.</li><li>\u2022 chronic dry cough while on ACE inhibitors,</li><li>\u2022 Angiotensin receptor blocker (ARB)</li><li>\u2022 correct course of action,</li><li>\u2022 s ARBs do not</li><li>\u2022 side effect.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e2b282a8",
      "audio": ""
    },
    {
      "text": "Which of the following drugs can result in prolongation of QT interval in ECG?",
      "options": [
        {
          "label": "A",
          "text": "Quinidine",
          "correct": true
        },
        {
          "label": "B",
          "text": "Lignocaine",
          "correct": false
        },
        {
          "label": "C",
          "text": "Ciprofloxacin",
          "correct": false
        },
        {
          "label": "D",
          "text": "Propranolol",
          "correct": false
        }
      ],
      "correct_answer": "A. Quinidine",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/08/screenshot-2024-05-08-113043.png"
      ],
      "explanation": "<p><strong>Ans. A) Quinidine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Lignocaine: Lignocaine (also known as lidocaine) is a class Ib anti-arrhythmic drug that predominantly blocks Na+ channels and is less likely to cause QT prolongation as its action is more specific to the fast sodium channels and it actually tends to shorten the action potential duration.</li><li>\u2022 Option B. Lignocaine:</li><li>\u2022 class Ib anti-arrhythmic drug</li><li>\u2022 blocks Na+ channels</li><li>\u2022 less</li><li>\u2022 QT prolongation</li><li>\u2022 more specific to the fast sodium channels</li><li>\u2022 shorten the action potential duration.</li><li>\u2022 Option C. Ciprofloxacin: Ciprofloxacin is a fluoroquinolone antibiotic . Although fluoroquinolones like sparfloxacin, levofloxacin, and moxifloxacin are associated with QT prolongation, ciprofloxacin is less implicated in causing this adverse effect when compared to other drugs in its class.</li><li>\u2022 Option C. Ciprofloxacin:</li><li>\u2022 fluoroquinolone antibiotic</li><li>\u2022 sparfloxacin, levofloxacin, and</li><li>\u2022 moxifloxacin</li><li>\u2022 QT prolongation, ciprofloxacin is less</li><li>\u2022 adverse effect</li><li>\u2022 Option D. Propranolol: Propranolol is a non-selective beta-blocker and is not commonly associated with QT prolongation . It acts on the beta-adrenergic receptors and can affect heart rate and contractility but not typically the QT interval.</li><li>\u2022 Option D. Propranolol:</li><li>\u2022 non-selective beta-blocker</li><li>\u2022 not</li><li>\u2022 QT prolongation</li><li>\u2022 beta-adrenergic receptors</li><li>\u2022 heart rate and contractility</li><li>\u2022 not</li><li>\u2022 QT interval.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Quinidine, a class Ia anti-arrhythmic drug , can cause QT interval prolongation on an ECG due to its blockade of potassium channels, which affects the repolarization phase of the cardiac action potential.</li><li>\u2022 Quinidine,</li><li>\u2022 class Ia anti-arrhythmic drug</li><li>\u2022 QT interval prolongation on an ECG</li><li>\u2022 blockade of potassium channels,</li><li>\u2022 repolarization phase of the cardiac action potential.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b2536843",
      "audio": ""
    },
    {
      "text": "Preferred drug for the treatment of uncomplicated grade 2 hypertension in a 48-year-old man is?",
      "options": [
        {
          "label": "A",
          "text": "Chlorthalidone",
          "correct": true
        },
        {
          "label": "B",
          "text": "Triamterene",
          "correct": false
        },
        {
          "label": "C",
          "text": "Spironolactone",
          "correct": false
        },
        {
          "label": "D",
          "text": "Furosemide",
          "correct": false
        }
      ],
      "correct_answer": "A. Chlorthalidone",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/08/screenshot-2024-05-08-114419.png"
      ],
      "explanation": "<p><strong>Ans. A) Chlorthalidone</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Triamterene: Triamterene is a potassium-sparing diuretic that is not typically used as first-line treatment for hypertension. It is often used in combination with other diuretics to prevent hypokalemia.</li><li>\u2022 Option B. Triamterene:</li><li>\u2022 potassium-sparing diuretic</li><li>\u2022 not</li><li>\u2022 first-line treatment for hypertension.</li><li>\u2022 used in combination</li><li>\u2022 diuretics to prevent hypokalemia.</li><li>\u2022 Option C. Spironolactone: Spironolactone is another potassium-sparing diuretic that also blocks the effects of aldosterone . While it can be used for hypertension , it is usually reserved for cases that are resistant to other treatments or for specific conditions like primary hyperaldosteronism.</li><li>\u2022 Option C. Spironolactone:</li><li>\u2022 potassium-sparing diuretic</li><li>\u2022 blocks the effects of aldosterone</li><li>\u2022 hypertension</li><li>\u2022 resistant to other treatments</li><li>\u2022 specific conditions like</li><li>\u2022 primary hyperaldosteronism.</li><li>\u2022 Option D. Furosemide: Furosemide is a loop diuretic that is primarily used for the treatment of edema associated with heart failure or renal disease. It is not typically used as first-line treatment for uncomplicated hypertension due to its shorter duration of action and greater risk for electrolyte imbalances.</li><li>\u2022 Option D. Furosemide:</li><li>\u2022 loop diuretic</li><li>\u2022 edema associated with heart failure</li><li>\u2022 renal disease.</li><li>\u2022 not</li><li>\u2022 first-line treatment for uncomplicated hypertension</li><li>\u2022 shorter duration of action and</li><li>\u2022 electrolyte imbalances.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The educational goal is to identify the preferred initial treatment options for hypertension. Thiazide-like diuretics such as chlorthalidone are recommended as first-line therapy for most patients with hypertension due to their effectiveness in lowering blood pressure and reducing the risk of cardiovascular events.</li><li>\u27a4 initial treatment</li><li>\u27a4 hypertension.</li><li>\u27a4 chlorthalidone are recommended as first-line therapy</li><li>\u27a4 hypertension</li><li>\u27a4 lowering</li><li>\u27a4 blood pressure and reducing the risk of cardiovascular events.</li><li>\u27a4 FIRST LINE DRUGS FOR DIFFERENT PATIENTS WITH HYPERTENSION</li><li>\u27a4 FIRST LINE DRUGS FOR DIFFERENT PATIENTS WITH HYPERTENSION</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "50383bc7",
      "audio": ""
    },
    {
      "text": "Which of the following drugs act as K channel opener?",
      "options": [
        {
          "label": "A",
          "text": "Spironolactone",
          "correct": false
        },
        {
          "label": "B",
          "text": "Amiloride",
          "correct": false
        },
        {
          "label": "C",
          "text": "Nicorandil",
          "correct": true
        },
        {
          "label": "D",
          "text": "Methyldopa",
          "correct": false
        }
      ],
      "correct_answer": "C. Nicorandil",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Nicorandil</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Spironolactone: Spironolactone is a potassium-sparing diuretic that works at the level of the distal convoluted tubule in the kidneys but does not act as a K channel opener in the cardiovascular system.</li><li>\u2022 Option A. Spironolactone:</li><li>\u2022 potassium-sparing diuretic</li><li>\u2022 at the level of the distal convoluted tubule</li><li>\u2022 does not act</li><li>\u2022 K channel opener</li><li>\u2022 Option B. Amiloride: Amiloride is also a potassium-sparing diuretic that affects ion channels in the kidneys , but again, it does not open potassium channels in vascular smooth muscle.</li><li>\u2022 Option B. Amiloride:</li><li>\u2022 potassium-sparing diuretic</li><li>\u2022 ion channels in the kidneys</li><li>\u2022 does not</li><li>\u2022 open potassium channels</li><li>\u2022 Option D. Methyldopa: Methyldopa is an antihypertensive medication that acts centrally as an alpha-2 agonist to lower blood pressure . It does not have K channel opening properties.</li><li>\u2022 Option D. Methyldopa:</li><li>\u2022 antihypertensive medication</li><li>\u2022 acts centrally as an alpha-2 agonist</li><li>\u2022 lower blood</li><li>\u2022 pressure</li><li>\u2022 does not</li><li>\u2022 K channel opening properties.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Nicorandil acts as a K channel opener and has nitrate-like properties, making it effective in the treatment of angina pectoris due to its ability to reduce myocardial oxygen demand and increase blood flow to the ischemic heart muscle.</li><li>\u27a4 Nicorandil</li><li>\u27a4 K channel opener and has nitrate-like properties,</li><li>\u27a4 treatment of angina pectoris</li><li>\u27a4 reduce myocardial oxygen demand</li><li>\u27a4 increase blood flow to the ischemic heart muscle.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "da88427b",
      "audio": ""
    },
    {
      "text": "A 55 yr. old male presented to emergency with severe acute chest pain, radiating to left shoulder and back in the last 20 minutes. It was associated with sweating. ECG is shown in the figure. Which of the following drug should be given to the patient?",
      "options": [
        {
          "label": "A",
          "text": "Amiodarone",
          "correct": false
        },
        {
          "label": "B",
          "text": "Adenosine",
          "correct": false
        },
        {
          "label": "C",
          "text": "Tenecteplase",
          "correct": true
        },
        {
          "label": "D",
          "text": "Verapamil",
          "correct": false
        }
      ],
      "correct_answer": "C. Tenecteplase",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/25/42.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Tenecteplase</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Amiodarone: Amiodarone is an antiarrhythmic medication that is not indicated as an initial treatment for acute myocardial infarction unless there are accompanying life-threatening arrhythmias.</li><li>\u2022 Option A. Amiodarone:</li><li>\u2022 antiarrhythmic medication</li><li>\u2022 not</li><li>\u2022 acute</li><li>\u2022 myocardial infarction</li><li>\u2022 life-threatening arrhythmias.</li><li>\u2022 Option B. Adenosine: Adenosine is typically used in the treatment of certain forms of supraventricular tachycardia and not in the setting of acute myocardial infarction.</li><li>\u2022 Option B. Adenosine:</li><li>\u2022 used</li><li>\u2022 supraventricular tachycardia</li><li>\u2022 not</li><li>\u2022 acute myocardial infarction.</li><li>\u2022 Option D. Verapamil: Verapamil is a calcium channel blocker that is generally contraindicated in the setting of acute myocardial infarction, especially with evidence of STEMI, as it can further depress myocardial contractility and lead to hemodynamic deterioration.</li><li>\u2022 Option D. Verapamil:</li><li>\u2022 calcium channel blocker</li><li>\u2022 contraindicated</li><li>\u2022 acute myocardial</li><li>\u2022 infarction,</li><li>\u2022 STEMI,</li><li>\u2022 depress myocardial contractility</li><li>\u2022 lead to hemodynamic</li><li>\u2022 deterioration.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The objective is to recognize the appropriate use of thrombolytic therapy in the treatment of STEMI when PCI is not immediately available. Prompt initiation of thrombolytic therapy can significantly improve outcomes in STEMI by restoring coronary blood flow and minimizing myocardial damage.</li><li>\u27a4 appropriate use of thrombolytic therapy</li><li>\u27a4 STEMI when PCI is not immediately</li><li>\u27a4 available.</li><li>\u27a4 Prompt</li><li>\u27a4 thrombolytic therapy</li><li>\u27a4 improve outcomes in STEMI</li><li>\u27a4 coronary blood flow</li><li>\u27a4 minimizing myocardial damage.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "59173095",
      "audio": ""
    },
    {
      "text": "Which of the following drugs is used for reversal of cerebral vasospasm and infarct following subarachnoid hemorrhage?",
      "options": [
        {
          "label": "A",
          "text": "Nimodipine",
          "correct": true
        },
        {
          "label": "B",
          "text": "Amlodipine",
          "correct": false
        },
        {
          "label": "C",
          "text": "Diltiazem",
          "correct": false
        },
        {
          "label": "D",
          "text": "Verapamil",
          "correct": false
        }
      ],
      "correct_answer": "A. Nimodipine",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Nimodipine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Amlodipine: While amlodipine is also a calcium channel blocker , it is not specifically indicated for cerebral vasospasm. It is more commonly used for hypertension and coronary artery disease.</li><li>\u2022 Option B. Amlodipine:</li><li>\u2022 calcium channel blocker</li><li>\u2022 cerebral vasospasm.</li><li>\u2022 hypertension and coronary artery disease.</li><li>\u2022 Option C. Diltiazem: Diltiazem is another calcium channel blocker with a broader cardiovascular effect profile and is not the drug of choice for cerebral vasospasm.</li><li>\u2022 Option C. Diltiazem:</li><li>\u2022 calcium channel blocker</li><li>\u2022 broader cardiovascular effect profile</li><li>\u2022 not</li><li>\u2022 cerebral vasospasm.</li><li>\u2022 Option D. Verapamil: Verapamil is a non-selective calcium channel blocker and is not specifically recommended for the treatment of cerebral vasospasm following subarachnoid hemorrhage.</li><li>\u2022 Option D. Verapamil:</li><li>\u2022 non-selective calcium channel blocker</li><li>\u2022 not</li><li>\u2022 cerebral vasospasm</li><li>\u2022 subarachnoid hemorrhage.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Nimodipine is used for the reversal of cerebral vasospasm and reducing mortality after subarachnoid hemorrhage, due to its s elective action on cerebral blood vessels.</li><li>\u27a4 Nimodipine</li><li>\u27a4 reversal of cerebral vasospasm and reducing mortality</li><li>\u27a4 subarachnoid hemorrhage,</li><li>\u27a4 elective action on cerebral blood vessels.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "44ad5601",
      "audio": ""
    },
    {
      "text": "In a patient with concomitant diabetes, anti-hypertensive agent of choice is?",
      "options": [
        {
          "label": "A",
          "text": "Thiazides",
          "correct": false
        },
        {
          "label": "B",
          "text": "Beta adrenergic blocker",
          "correct": false
        },
        {
          "label": "C",
          "text": "ACE inhibitor",
          "correct": true
        },
        {
          "label": "D",
          "text": "Diazoxide",
          "correct": false
        }
      ],
      "correct_answer": "C. ACE inhibitor",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) ACE inhibitor</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Thiazides: Thiazide diuretics are effective antihypertensive agents but can affect carbohydrate metabolism and are not the first choice in patients with diabetes , as they can potentially worsen glycemic control.</li><li>\u2022 Option A. Thiazides:</li><li>\u2022 antihypertensive</li><li>\u2022 affect carbohydrate metabolism</li><li>\u2022 not</li><li>\u2022 first choice in patients with diabetes</li><li>\u2022 worsen glycemic control.</li><li>\u2022 Option B. Beta adrenergic blocker: Beta-blockers can mask symptoms of hypoglycemia and may also affect lipid metabolism. Although they are effective for blood pressure control, they are not typically the first-line choice in diabetic patients unless there are other compelling indications such as heart failure or post-myocardial infarction.</li><li>\u2022 Option B. Beta adrenergic blocker:</li><li>\u2022 can mask</li><li>\u2022 hypoglycemia</li><li>\u2022 lipid metabolism.</li><li>\u2022 effective for blood pressure control,</li><li>\u2022 not</li><li>\u2022 first-line choice in diabetic patients</li><li>\u2022 other compelling indications such as heart failure or post-myocardial infarction.</li><li>\u2022 Option D. Diazoxide: Diazoxide is a vasodilator that can actually increase blood sugar levels by inhibiting insulin release from the pancreas . It is not used for routine treatment of hypertension and is certainly not the drug of choice in patients with diabetes.</li><li>\u2022 Option D. Diazoxide:</li><li>\u2022 vasodilator</li><li>\u2022 increase blood sugar levels</li><li>\u2022 inhibiting insulin release</li><li>\u2022 pancreas</li><li>\u2022 not</li><li>\u2022 hypertension</li><li>\u2022 not the drug of choice in patients with diabetes.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The educational goal is to understand the appropriate choice of antihypertensive medication in patients with diabetes . ACE inhibitors offer renal protection and do not worsen glycemic control, making them a superior option for this patient population. Other properties of ACE inhibitors are also important for entrance exams.</li><li>\u27a4 appropriate choice of antihypertensive medication in patients with diabetes</li><li>\u27a4 ACE</li><li>\u27a4 inhibitors offer renal protection</li><li>\u27a4 do not</li><li>\u27a4 glycemic control,</li><li>\u27a4 Properties of ACE inhibitors</li><li>\u27a4 Properties of ACE inhibitors</li><li>\u27a4 C - C ough</li><li>\u27a4 C</li><li>\u27a4 C</li><li>\u27a4 A - A ngioedema</li><li>\u27a4 A</li><li>\u27a4 A</li><li>\u27a4 P - P rodrugs (except captopril and Lisinopril)</li><li>\u27a4 P</li><li>\u27a4 P</li><li>\u27a4 T - T aste disturbances</li><li>\u27a4 T</li><li>\u27a4 T</li><li>\u27a4 O - O rthostatic hypotension (when combined with diuretics)</li><li>\u27a4 O</li><li>\u27a4 O</li><li>\u27a4 P - P regnancy (contra- indicated)</li><li>\u27a4 P</li><li>\u27a4 P</li><li>\u27a4 R - bilateral R enal artery stenosis (contra-indicated)</li><li>\u27a4 R</li><li>\u27a4 R</li><li>\u27a4 I - I ncreased K+ (contra-indicated)</li><li>\u27a4 I</li><li>\u27a4 I</li><li>\u27a4 L - L ower the risk of diabetic nephropathy (Preferred drug in diabetic patients with hypertension)</li><li>\u27a4 L</li><li>\u27a4 L</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "5624d58f",
      "audio": ""
    },
    {
      "text": "Which of the following is a Rho kinase inhibitor?",
      "options": [
        {
          "label": "A",
          "text": "Fasudil",
          "correct": true
        },
        {
          "label": "B",
          "text": "Ranolazine",
          "correct": false
        },
        {
          "label": "C",
          "text": "Trimetazidine",
          "correct": false
        },
        {
          "label": "D",
          "text": "Ivabradine",
          "correct": false
        }
      ],
      "correct_answer": "A. Fasudil",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Fasudil</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Ranolazine: Ranolazine is an anti-anginal medication. It works by inhibiting the late phase of the sodium current in the cardiac myocytes , thus reducing intracellular calcium overload and myocardial oxygen consumption. It does not act as a Rho kinase inhibitor.</li><li>\u2022 Option B. Ranolazine:</li><li>\u2022 anti-anginal medication.</li><li>\u2022 inhibiting the late phase of the sodium</li><li>\u2022 cardiac myocytes</li><li>\u2022 reducing intracellular calcium overload</li><li>\u2022 myocardial oxygen consumption.</li><li>\u2022 does not</li><li>\u2022 Rho kinase</li><li>\u2022 inhibitor.</li><li>\u2022 Option C. Trimetazidine: Trimetazidine is an anti-ischemic (anti-anginal) metabolic agent that improves myocardial glucose utilization through inhibition of fatty acid metabolism. This action helps to maintain energy production in ischemic heart cells. Trimetazidine is not a Rho kinase inhibitor.</li><li>\u2022 Option C. Trimetazidine:</li><li>\u2022 anti-ischemic (anti-anginal) metabolic agent</li><li>\u2022 improves myocardial glucose</li><li>\u2022 inhibition of fatty acid metabolism.</li><li>\u2022 maintain energy production in ischemic heart cells.</li><li>\u2022 Trimetazidine is not a Rho kinase inhibitor.</li><li>\u2022 Option D. Ivabradine: Ivabradine is a heart rate-reducing agent that works by inhibiting the If (funny) channel in the sinoatrial node of the heart , leading to a reduction in heart rate and myocardial oxygen demand. It is used for the treatment of chronic heart failure and stable angina pectoris in patients who cannot take beta-blockers . Ivabradine is not a Rho kinase inhibitor.</li><li>\u2022 Option D. Ivabradine:</li><li>\u2022 heart rate-reducing agent</li><li>\u2022 inhibiting the If (funny) channel in the sinoatrial node</li><li>\u2022 of the heart</li><li>\u2022 reduction in heart rate and myocardial oxygen demand.</li><li>\u2022 chronic heart failure</li><li>\u2022 stable angina pectoris</li><li>\u2022 cannot take beta-blockers</li><li>\u2022 Ivabradine is not a Rho kinase inhibitor.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The educational goal is to understand the different mechanisms of action of various anti-anginal drugs. Fasudil as a Rho kinase inhibitor contrasts with ranolazine, trimetazidine, and ivabradine, which have different mechanisms.</li><li>\u27a4 different mechanisms of action</li><li>\u27a4 anti-anginal drugs. Fasudil as a Rho kinase</li><li>\u27a4 inhibitor contrasts</li><li>\u27a4 ranolazine, trimetazidine, and ivabradine,</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "2e3dd569",
      "audio": ""
    },
    {
      "text": "Identify the antiarrhythmic agent with the following mechanism of action?",
      "options": [
        {
          "label": "A",
          "text": "Flecainide",
          "correct": true
        },
        {
          "label": "B",
          "text": "Tocainide",
          "correct": false
        },
        {
          "label": "C",
          "text": "Procainamide",
          "correct": false
        },
        {
          "label": "D",
          "text": "Ibutilide",
          "correct": false
        }
      ],
      "correct_answer": "A. Flecainide",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/02/14/whatsapp-image-2024-02-14-at-35057-pm.jpeg"
      ],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/25/image-3-1.jpg"
      ],
      "explanation": "<p><strong>Ans. A) Flecainide</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Tocainide: Tocainide is a Class IB antiarrhythmic agent. Class IB drugs tend to shorten the action potential duration rather than having no change in repolarization.</li><li>\u2022 Option B. Tocainide:</li><li>\u2022 Class IB antiarrhythmic agent.</li><li>\u2022 shorten the action potential</li><li>\u2022 no change in repolarization.</li><li>\u2022 Option C. Procainamide: Procainamide is a Class IA antiarrhythmic agent that not only blocks sodium channels but also has a moderate effect on repolarization, leading to a slight prolongation of the action potential, which is not depicted in the graph.</li><li>\u2022 Option C. Procainamide:</li><li>\u2022 a Class IA antiarrhythmic agent</li><li>\u2022 not only blocks sodium channels</li><li>\u2022 moderate effect on repolarization,</li><li>\u2022 slight prolongation of the action potential,</li><li>\u2022 Option D. Ibutilide: Ibutilide is a Class III antiarrhythmic drug that acts by prolonging repolarization through potassium channel blockade, which would lengthen the action potential, contrary to what is shown in the graph.</li><li>\u2022 Option D. Ibutilide:</li><li>\u2022 Class III antiarrhythmic drug</li><li>\u2022 prolonging repolarization</li><li>\u2022 potassium channel</li><li>\u2022 blockade,</li><li>\u2022 lengthen the action potential,</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The educational goal is to recognize the electrophysiologic profiles of different classes of antiarrhythmic drugs. Class IC antiarrhythmics like flecainide are characterized by their potent sodium channel-blocking effects with minimal impact on the duration of the action potential. Understanding these properties is important for the appropriate selection and use of antiarrhythmic drugs in clinical practice.</li><li>\u27a4 electrophysiologic profiles</li><li>\u27a4 different classes of antiarrhythmic drugs.</li><li>\u27a4 Class IC</li><li>\u27a4 antiarrhythmics like flecainide</li><li>\u27a4 potent sodium channel-blocking effects</li><li>\u27a4 minimal impact</li><li>\u27a4 duration of the action potential.</li><li>\u27a4 appropriate selection and use of antiarrhythmic drugs in clinical practice.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "74cdabd5",
      "audio": ""
    },
    {
      "text": "Which of the following is NOT true about the use of \u03b2 blockers in CHF?",
      "options": [
        {
          "label": "A",
          "text": "These should be started at a very low dose and slowly titrated upwards",
          "correct": false
        },
        {
          "label": "B",
          "text": "Carvedilol is the most widely used \u03b2 blocker",
          "correct": false
        },
        {
          "label": "C",
          "text": "These are drug of choice in acute decompensated heart failure",
          "correct": true
        },
        {
          "label": "D",
          "text": "These can reduce mortality in CHF patients",
          "correct": false
        }
      ],
      "correct_answer": "C. These are drug of choice in acute decompensated heart failure",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) These are drug of choice in acute decompensated heart failure</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. These should be started at a very low dose and slowly titrated upwards: This is correct and a key principle in the chronic management of CHF . Beta blockers need to be started at low doses to avoid abrupt changes in cardiac function and allow for patient tolerance.</li><li>\u2022 Option A. These should be started at a very low dose and slowly titrated upwards:</li><li>\u2022 correct</li><li>\u2022 chronic</li><li>\u2022 CHF</li><li>\u2022 low doses to avoid abrupt changes in cardiac function</li><li>\u2022 Option B. Carvedilol is the most widely used \u03b2 blocker: While carvedilol is one of the commonly used beta blockers in CHF, saying it is \" the most widely used \" may not be true in all settings, as metoprolol and bisoprolol are also commonly prescribed. However, this statement is generally accepted in practice.</li><li>\u2022 Option B. Carvedilol is the most widely used \u03b2 blocker:</li><li>\u2022 carvedilol</li><li>\u2022 beta blockers in CHF,</li><li>\u2022 the most widely used</li><li>\u2022 not be true in all settings,</li><li>\u2022 metoprolol and bisoprolol</li><li>\u2022 also commonly prescribed.</li><li>\u2022 Option D. These can reduce mortality in CHF patients: This is true . Beta blockers have been shown to decrease mortality in chronic CHF by improving left ventricular function , reducing arrhythmias, and limiting cardiac remodeling.</li><li>\u2022 Option D. These can reduce mortality in CHF patients:</li><li>\u2022 true</li><li>\u2022 Beta blockers</li><li>\u2022 decrease mortality in chronic</li><li>\u2022 CHF</li><li>\u2022 improving left ventricular function</li><li>\u2022 reducing arrhythmias, and limiting cardiac remodeling.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Beta blockers should not be used as the drug of choice in acute decompensated heart failure but are essential for the management of chronic CHF , where they have been shown to reduce mortality and morbidity.</li><li>\u27a4 Beta blockers</li><li>\u27a4 not</li><li>\u27a4 drug of choice</li><li>\u27a4 acute decompensated heart failure</li><li>\u27a4 chronic CHF</li><li>\u27a4 reduce mortality and morbidity.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "38063111",
      "audio": ""
    },
    {
      "text": "All the following drugs can cause gynecomastia except:",
      "options": [
        {
          "label": "A",
          "text": "Digoxin",
          "correct": false
        },
        {
          "label": "B",
          "text": "Amiloride",
          "correct": true
        },
        {
          "label": "C",
          "text": "Cimetidine",
          "correct": false
        },
        {
          "label": "D",
          "text": "Ketoconazole",
          "correct": false
        }
      ],
      "correct_answer": "B. Amiloride",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Amiloride</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Digoxin: Digoxin, a cardiac glycoside, has been associated with gynecomastia as a rare adverse effect, possibly due to its estrogen-like effects and alterations in hormone metabolism.</li><li>\u2022 Option A. Digoxin:</li><li>\u2022 Digoxin,</li><li>\u2022 cardiac glycoside,</li><li>\u2022 gynecomastia</li><li>\u2022 adverse effect,</li><li>\u2022 estrogen-like effects and alterations in hormone metabolism.</li><li>\u2022 Option C. Cimetidine: Cimetidine, a histamine H2 receptor antagonist , can cause gynecomastia by blocking androgen receptors and increasing prolactin secretion.</li><li>\u2022 Option C. Cimetidine:</li><li>\u2022 histamine H2 receptor antagonist</li><li>\u2022 gynecomastia</li><li>\u2022 blocking androgen receptors</li><li>\u2022 increasing prolactin secretion.</li><li>\u2022 Option D. Ketoconazole: Ketoconazole, an antifungal agent, can inhibit testosterone synthesis by blocking cytochrome P450 enzymes, leading to elevated estrogen levels and resulting in gynecomastia.</li><li>\u2022 Option D. Ketoconazole:</li><li>\u2022 an antifungal agent,</li><li>\u2022 inhibit testosterone synthesis</li><li>\u2022 blocking cytochrome P450</li><li>\u2022 elevated estrogen levels</li><li>\u2022 gynecomastia.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The educational goal is to recognize medications associated with the development of gynecomastia a s an adverse effect.</li><li>\u27a4 recognize medications associated with the development of gynecomastia a</li><li>\u27a4 IMPORTANT DRUGS CAUSING GYNAECOMASTIA:</li><li>\u27a4 IMPORTANT DRUGS CAUSING GYNAECOMASTIA:</li><li>\u27a4 DI: DI goxin</li><li>\u27a4 DI: DI</li><li>\u27a4 S: S pironolactone</li><li>\u27a4 S: S</li><li>\u27a4 C: C imetidine, K etoconazole</li><li>\u27a4 C: C</li><li>\u27a4 K</li><li>\u27a4 O: O estrogens</li><li>\u27a4 O: O</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "6064dc48",
      "audio": ""
    },
    {
      "text": "All the following statements about the Nitrates in Angina are true except?",
      "options": [
        {
          "label": "A",
          "text": "Reduce preload",
          "correct": false
        },
        {
          "label": "B",
          "text": "Sildenafil may pronounce hypotension and should never be combined",
          "correct": false
        },
        {
          "label": "C",
          "text": "Cause redistribution of coronary blood flow",
          "correct": false
        },
        {
          "label": "D",
          "text": "Tolerance is most seen in sublingual administration of nitrates",
          "correct": true
        }
      ],
      "correct_answer": "D. Tolerance is most seen in sublingual administration of nitrates",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Tolerance is most seen in sublingual administration of nitrates</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Reduce preload: True . Nitrates predominantly dilate veins, leading to a reduction in preload, which decreases the amount of blood returning to the heart , thereby reducing the work the hear t has to do and the oxygen demand.</li><li>\u2022 Option A. Reduce preload:</li><li>\u2022 True</li><li>\u2022 Nitrates predominantly dilate veins,</li><li>\u2022 reduction in preload,</li><li>\u2022 decreases the amount</li><li>\u2022 blood returning to the heart</li><li>\u2022 reducing the work the hear</li><li>\u2022 do and the oxygen demand.</li><li>\u2022 Option B. Sildenafil may pronounce hypotension and should never be combined: True. Combining nitrates with sildenafil can lead to dangerous potentiation of vasodilatory effects, resulting in severe hypotension, myocardial infarction, and even death.</li><li>\u2022 Option B. Sildenafil may pronounce hypotension and should never be combined:</li><li>\u2022 True.</li><li>\u2022 nitrates with sildenafil</li><li>\u2022 vasodilatory effects,</li><li>\u2022 severe hypotension,</li><li>\u2022 myocardial infarction, and even death.</li><li>\u2022 Option C. Cause redistribution of coronary blood flow: True . Nitrates preferentially dilate larger conducting coronary arteries over arterioles , which may facilitate increased blood flow to ischemic areas of the heart in patients with angina.</li><li>\u2022 Option C. Cause redistribution of coronary blood flow:</li><li>\u2022 True</li><li>\u2022 dilate larger</li><li>\u2022 conducting coronary arteries</li><li>\u2022 arterioles</li><li>\u2022 increased blood flow to ischemic areas of the heart</li><li>\u2022 angina.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 In the context of angina treatment, nitrates are known to reduce preload and can cause redistribution of coronary blood flow , but significant tolerance is not typically associated with intermittent sublingual administration. It is also critical to avoid the combination of nitrates with sildenafil due to the risk of severe hypotension.</li><li>\u27a4 nitrates</li><li>\u27a4 reduce preload</li><li>\u27a4 redistribution of coronary blood flow</li><li>\u27a4 significant tolerance</li><li>\u27a4 not</li><li>\u27a4 with intermittent sublingual administration.</li><li>\u27a4 avoid the</li><li>\u27a4 combination of nitrates with sildenafil</li><li>\u27a4 risk of severe hypotension.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ac6f8347",
      "audio": ""
    },
    {
      "text": "Which of the following antiarrhythmic drug is contraindicated in a patient with interstitial lung disease?",
      "options": [
        {
          "label": "A",
          "text": "Amiodarone",
          "correct": true
        },
        {
          "label": "B",
          "text": "Sotalol",
          "correct": false
        },
        {
          "label": "C",
          "text": "Quinidine",
          "correct": false
        },
        {
          "label": "D",
          "text": "Lignocaine",
          "correct": false
        }
      ],
      "correct_answer": "A. Amiodarone",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Amiodarone</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Sotalol: Sotalol is also a class III antiarrhythmic drug but does not carry the same risk for inducing pulmonary toxicity as amiodarone.</li><li>\u2022 Option B. Sotalol:</li><li>\u2022 class III antiarrhythmic drug</li><li>\u2022 does not</li><li>\u2022 pulmonary toxicity as</li><li>\u2022 amiodarone.</li><li>\u2022 Option C. Quinidine: Quinidine is a class Ia antiarrhythmic drug and is not associated with interstitial lung disease as a side effect.</li><li>\u2022 Option C. Quinidine:</li><li>\u2022 class Ia antiarrhythmic drug</li><li>\u2022 not</li><li>\u2022 interstitial lung disease</li><li>\u2022 Option D. Lignocaine: Lignocaine (lidocaine) is a class Ib antiarrhythmic drug used mainly in acute settings for ventricular arrhythmias and does not have pulmonary toxicity akin to amiodarone.</li><li>\u2022 Option D. Lignocaine:</li><li>\u2022 class Ib antiarrhythmic</li><li>\u2022 acute settings for ventricular</li><li>\u2022 arrhythmias</li><li>\u2022 does not</li><li>\u2022 pulmonary toxicity akin to amiodarone.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Amiodarone, while effective as a broad-spectrum antiarrhythmic agent , is contraindicated in patients with interstitial lung disease because of its serious side effect of pulmonary alveolitis and fibrosis.</li><li>\u27a4 Amiodarone,</li><li>\u27a4 broad-spectrum antiarrhythmic agent</li><li>\u27a4 contraindicated in patients</li><li>\u27a4 interstitial lung disease</li><li>\u27a4 side effect of pulmonary alveolitis and fibrosis.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b0af007f",
      "audio": ""
    },
    {
      "text": "Which of the following drugs block late inward sodium ion channels?",
      "options": [
        {
          "label": "A",
          "text": "Ranolazine",
          "correct": true
        },
        {
          "label": "B",
          "text": "Trimetazidine",
          "correct": false
        },
        {
          "label": "C",
          "text": "Ivabradine",
          "correct": false
        },
        {
          "label": "D",
          "text": "Fasudil",
          "correct": false
        }
      ],
      "correct_answer": "A. Ranolazine",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Ranolazine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Trimetazidine: Trimetazidine acts as a partial fatty acid oxidation inhibitor, optimizing the energy metabolism of the heart during ischemia, but it does not block sodium channels.</li><li>\u2022 Option B. Trimetazidine:</li><li>\u2022 Option C. Ivabradine: Ivabradine selectively inhibits the funny current (If) in the sinoatrial node, resulting in heart rate reduction, which can be beneficial in conditions like angina and heart failure, but it is not a sodium channel blocker.</li><li>\u2022 Option C. Ivabradine:</li><li>\u2022 Option D. Fasudil: Fasudil is a Rho-kinase inhibitor with vasodilatory effects and does not block sodium channels.</li><li>\u2022 Option D. Fasudil:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Ranolazine is a late inward sodium channel blocker that can be used to treat chronic angina by improving myocardial relaxation and decreasing ischemia without major effects on heart rate or blood pressure.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "82633a83",
      "audio": ""
    },
    {
      "text": "Which of the following sites is least commonly preferred for insulin injection?",
      "options": [
        {
          "label": "A",
          "text": "Anterior thigh",
          "correct": false
        },
        {
          "label": "B",
          "text": "Lateral thigh",
          "correct": false
        },
        {
          "label": "C",
          "text": "Upper arm",
          "correct": false
        },
        {
          "label": "D",
          "text": "Around umbilicus",
          "correct": true
        }
      ],
      "correct_answer": "D. Around umbilicus",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture5.jpg"
      ],
      "explanation": "<p><strong>Ans. D. Around umbilicus</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Anterior thigh and B. Lateral thigh C. Upper arm: These areas are common for insulin injections and provide consistent absorption , although generally slower compared to the abdominal wall.</li><li>\u2022 Option A. Anterior thigh</li><li>\u2022 B. Lateral thigh C. Upper arm:</li><li>\u2022 common for insulin injections</li><li>\u2022 consistent</li><li>\u2022 absorption</li><li>\u2022 slower</li><li>\u2022 abdominal wall.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 SITES OF INSULIN INJECTION</li><li>\u27a4 SITES OF INSULIN INJECTION</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "9f2ae976",
      "audio": ""
    },
    {
      "text": "A 60-year-old patient with Type 2 diabetes mellitus is being evaluated for potential adjustments to their diabetes management plan. The patient's current regimen includes metformin and lifestyle modifications. However, recent glycemic control has been suboptimal, and the healthcare provider is considering adding an additional medication to enhance insulin secretion, aiming to achieve better glucose control. Which of the following antidiabetic drugs act by increasing the secretion of insulin, making it a suitable addition to this patient's diabetes management plan?",
      "options": [
        {
          "label": "A",
          "text": "Pramlintide",
          "correct": false
        },
        {
          "label": "B",
          "text": "Metformin",
          "correct": false
        },
        {
          "label": "C",
          "text": "Exenatide",
          "correct": true
        },
        {
          "label": "D",
          "text": "Rosiglitazone",
          "correct": false
        }
      ],
      "correct_answer": "C. Exenatide",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture4.jpg"
      ],
      "explanation": "<p><strong>Ans. C. Exenatide</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Pramlintide : It is an amylin analogu e that mimics the natural hormone amylin . Pramlintide slows gastric emptying, reduces postprandial glucagon secretion, and promotes satiety , leading to decreased caloric intake . However, it does not directly increase insulin secretion.</li><li>\u2022 Option A. Pramlintide</li><li>\u2022 amylin analogu</li><li>\u2022 mimics the natural hormone amylin</li><li>\u2022 slows gastric emptying,</li><li>\u2022 reduces postprandial glucagon secretion,</li><li>\u2022 promotes satiety</li><li>\u2022 decreased caloric intake</li><li>\u2022 does not</li><li>\u2022 increase insulin secretion.</li><li>\u2022 Option B. Metformin : This is a biguanide, which is already part of the patient's regimen. Metformin works mainly by decreasing hepatic glucose production and improving insulin sensitivity but does not increase insulin secretion.</li><li>\u2022 Option B. Metformin</li><li>\u2022 biguanide,</li><li>\u2022 decreasing</li><li>\u2022 hepatic glucose production</li><li>\u2022 insulin sensitivity</li><li>\u2022 does not</li><li>\u2022 increase insulin secretion.</li><li>\u2022 Option D. Rosiglitazone : It belongs to the thiazolidinedione class of drugs, which work by increasing insulin sensitivity rather than directly stimulating insulin secretion.</li><li>\u2022 Option D. Rosiglitazone</li><li>\u2022 thiazolidinedione</li><li>\u2022 increasing insulin sensitivity</li><li>\u2022 stimulating insulin secretion.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 ANTI-DIABETIC DRUGS THAT ACT BY INCREASING THE SECRETION OF INSULIN:</li><li>\u27a4 ANTI-DIABETIC DRUGS THAT ACT BY INCREASING THE SECRETION OF INSULIN:</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "06a65bd8",
      "audio": ""
    },
    {
      "text": "The given figure shows the mechanism of action of Drug Y in treatment of osteoporosis. Which of the following best represents drug Y?",
      "options": [
        {
          "label": "A",
          "text": "Raloxifene",
          "correct": false
        },
        {
          "label": "B",
          "text": "Bisphosphonates",
          "correct": false
        },
        {
          "label": "C",
          "text": "Teriparatide",
          "correct": false
        },
        {
          "label": "D",
          "text": "Denosumab",
          "correct": true
        }
      ],
      "correct_answer": "D. Denosumab",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture16.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D. Denosumab</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Raloxifene: Incorrect for this mechanism. Raloxifene is a selective estrogen receptor modulator (SERM) that mimics estrogen's bone-protective effect s by reducing osteoclast activity, but it does not work by targeting the RANKL-RANK interaction.</li><li>\u2022 Option A. Raloxifene:</li><li>\u2022 Incorrect</li><li>\u2022 Raloxifene is a selective estrogen receptor modulator (SERM)</li><li>\u2022 estrogen's bone-protective effect</li><li>\u2022 reducing osteoclast activity,</li><li>\u2022 does not</li><li>\u2022 RANKL-RANK interaction.</li><li>\u2022 Option B. Bisphosphonates: Also incorrect. Bisphosphonates inhibit osteoclast-mediated bone resorption by inducing osteoclast apoptosis and interfering with the mevalonate pathway , not by RANKL inhibition.</li><li>\u2022 Option B. Bisphosphonates:</li><li>\u2022 incorrect.</li><li>\u2022 inhibit</li><li>\u2022 osteoclast-mediated bone resorption</li><li>\u2022 osteoclast</li><li>\u2022 apoptosis</li><li>\u2022 mevalonate pathway</li><li>\u2022 Option C. Teriparatide: Incorrect for this illustration. Teriparatide, a recombinant form of parathyroid hormone , primarily works by stimulating osteoblasts to promote bone formation rather than inhibiting osteoclasts.</li><li>\u2022 Option C. Teriparatide:</li><li>\u2022 Incorrect</li><li>\u2022 Teriparatide,</li><li>\u2022 parathyroid hormone</li><li>\u2022 stimulating osteoblasts</li><li>\u2022 bone formation rather than inhibiting osteoclasts.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Denosumab is used in the treatment of osteoporosis by targeting the RANKL-RANK interaction , effectively inhibiting osteoclast formation and activity, thus decreasing bone resorption.</li><li>\u27a4 Denosumab</li><li>\u27a4 osteoporosis by targeting the RANKL-RANK interaction</li><li>\u27a4 inhibiting osteoclast</li><li>\u27a4 decreasing bone resorption.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "9ce43baf",
      "audio": ""
    },
    {
      "text": "A 22-year-old female, Neeta, presented to you with complaints of headache and vomiting for 2 months. She has amenorrhea, but the urine pregnancy test is negative. She also complained of secretion of milk from the breasts. A provisional diagnosis of hyperprolactinemia was made, and MRI was suggested. MRI confirmed the presence of a large pituitary adenoma. Neeta was advised surgery; however, she is not willing to undergo surgery. Which of the following medications is most likely to be prescribed to control her symptoms?",
      "options": [
        {
          "label": "A",
          "text": "Sumatriptan",
          "correct": false
        },
        {
          "label": "B",
          "text": "Bromocriptine",
          "correct": true
        },
        {
          "label": "C",
          "text": "Ergotamine",
          "correct": false
        },
        {
          "label": "D",
          "text": "Allopurinol",
          "correct": false
        }
      ],
      "correct_answer": "B. Bromocriptine",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B. Bromocriptine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Sumatriptan : Sumatriptan is a medication used to treat acute migraine headaches . It is a serotonin receptor agonist that causes vasoconstriction of cranial blood vessels. It is not used in the treatment of hyperprolactinemia or pituitary adenomas.</li><li>\u2022 Option A. Sumatriptan</li><li>\u2022 used to treat acute migraine headaches</li><li>\u2022 serotonin receptor agonist</li><li>\u2022 vasoconstriction of cranial blood vessels.</li><li>\u2022 not</li><li>\u2022 hyperprolactinemia or pituitary adenomas.</li><li>\u2022 Option C. Ergotamine : Ergotamine is used for the treatment of migraine headaches . It is an ergot alkaloid that causes vasoconstriction. It does not reduce prolactin levels or treat pituitary adenomas.</li><li>\u2022 Option C. Ergotamine</li><li>\u2022 used for</li><li>\u2022 migraine headaches</li><li>\u2022 ergot alkaloid</li><li>\u2022 vasoconstriction.</li><li>\u2022 does not</li><li>\u2022 prolactin levels or treat pituitary adenomas.</li><li>\u2022 Option D. Allopurinol : Allopurinol is used to decrease high blood uric acid levels , as seen in gout and certain types of kidney stones. It is not relevant to the treatment of hyperprolactinemia or pituitary adenomas.</li><li>\u2022 Option D. Allopurinol</li><li>\u2022 decrease high blood uric acid levels</li><li>\u2022 gout</li><li>\u2022 kidney stones.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Bromocriptine is the appropriate pharmacological treatment for hyperprolactinemia caused by a pituitary adenoma , especially when surgery is not an option.</li><li>\u27a4 Bromocriptine</li><li>\u27a4 hyperprolactinemia</li><li>\u27a4 pituitary adenoma</li><li>\u27a4 Bromocriptine is the preferred choice due to its dual role in reducing prolactin levels and potentially decreasing the size of the adenoma , thus addressing both the hormonal imbalance and its physical cause.</li><li>\u27a4 Bromocriptine</li><li>\u27a4 choice</li><li>\u27a4 reducing prolactin levels and potentially decreasing the size of the</li><li>\u27a4 adenoma</li><li>\u27a4 both</li><li>\u27a4 hormonal imbalance and its physical cause.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "d67646f7",
      "audio": ""
    },
    {
      "text": "An obese diabetic patient was on metformin monotherapy, but his sugar levels were not well controlled. He is allergic to sulfa drugs and does not comply with injectable drugs. He has a history of pancreatitis, and family history of bladder carcinoma. In view of the raised glucose levels, you wish to add another anti-diabetic drug. Which one would you prefer?",
      "options": [
        {
          "label": "A",
          "text": "Liraglutide",
          "correct": false
        },
        {
          "label": "B",
          "text": "Sitagliptin",
          "correct": false
        },
        {
          "label": "C",
          "text": "Canagliflozin",
          "correct": true
        },
        {
          "label": "D",
          "text": "Pioglitazone",
          "correct": false
        }
      ],
      "correct_answer": "C. Canagliflozin",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture10.jpg",
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture11.jpg"
      ],
      "explanation": "<p><strong>Ans. C. Canagliflozin</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Liraglutide: Not suitable as it is an injectable GLP-1 receptor agonist, and the patient has a non-compliance issue with injectable medications.</li><li>\u2022 Option A. Liraglutide:</li><li>\u2022 Not</li><li>\u2022 injectable GLP-1 receptor agonist,</li><li>\u2022 non-compliance issue</li><li>\u2022 Option B. Sitagliptin: A DPP-4 inhibitor, which has been associated with cases of pancreatitis , making it a less suitable option for a patient with a history of this condition.</li><li>\u2022 Option B. Sitagliptin:</li><li>\u2022 DPP-4 inhibitor,</li><li>\u2022 cases of pancreatitis</li><li>\u2022 less suitable</li><li>\u2022 Option D. Pioglitazone: A thiazolidinedione that has been associated with an i ncreased risk of bladder cancer , especially in individuals with a family history of the disease , thus contraindicating its use in this patient.</li><li>\u2022 Option D. Pioglitazone:</li><li>\u2022 thiazolidinedione</li><li>\u2022 ncreased risk of bladder cancer</li><li>\u2022 family history of the disease</li><li>\u2022 contraindicating its use in this patient.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "48684a4a",
      "audio": ""
    },
    {
      "text": "All the following are contraindications for the use of metformin except?",
      "options": [
        {
          "label": "A",
          "text": "Hypotensive state",
          "correct": false
        },
        {
          "label": "B",
          "text": "Alcoholics",
          "correct": false
        },
        {
          "label": "C",
          "text": "Renal failure",
          "correct": false
        },
        {
          "label": "D",
          "text": "Hypokalemia",
          "correct": true
        }
      ],
      "correct_answer": "D. Hypokalemia",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture1.jpg"
      ],
      "explanation": "<p><strong>Ans. D. Hypokalemia</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Hypotensive state : While not a direct contraindication, caution is advised in conditions that may predispose patients to hypotension , as low perfusion may increase the risk of metformin induced lactic acidosis.</li><li>\u2022 Option A. Hypotensive state</li><li>\u2022 not a direct contraindication,</li><li>\u2022 predispose patients to hypotension</li><li>\u2022 low perfusion</li><li>\u2022 increase the risk of metformin</li><li>\u2022 lactic acidosis.</li><li>\u2022 Option B. Alcoholics : Chronic and excessive alcohol consumption is a contraindication for metformin use due to the increased risk of lactic acidosis , especially in cases of hepatic impairment and acute alcohol intoxication.</li><li>\u2022 Option B. Alcoholics</li><li>\u2022 Chronic and excessive alcohol</li><li>\u2022 contraindication for metformin</li><li>\u2022 increased risk of lactic acidosis</li><li>\u2022 hepatic impairment and acute alcohol intoxication.</li><li>\u2022 Option C. Renal failure : Renal failure or significant renal impairment is a contraindication for the use of metformin due to the increased risk of accumulating metformin and subsequent lactic acidosis . Latest guidelines regarding use of metformin in renal dysfunction include:</li><li>\u2022 Option C. Renal failure</li><li>\u2022 renal impairment is a contraindication</li><li>\u2022 metformin</li><li>\u2022 increased risk of accumulating metformin</li><li>\u2022 lactic acidosis</li><li>\u2022 metformin in renal dysfunction</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Risk factors for metformin induced lactic acidosis :</li><li>\u27a4 Risk factors for metformin induced lactic acidosis</li><li>\u27a4 :</li><li>\u27a4 Hepatic failure Renal failure Alcoholics Metabolic acidosis Elderly Conditions predisposing to hypoxia (Shock, CHF, Severe anemia, Major surgery etc.)</li><li>\u27a4 Hepatic failure</li><li>\u27a4 Renal failure</li><li>\u27a4 Alcoholics</li><li>\u27a4 Metabolic acidosis</li><li>\u27a4 Elderly</li><li>\u27a4 Conditions predisposing to hypoxia (Shock, CHF, Severe anemia, Major surgery etc.)</li><li>\u27a4 Mnemonic:</li><li>\u27a4 Mnemonic:</li><li>\u27a4 MET: MET abolic acidosis</li><li>\u27a4 MET: MET</li><li>\u27a4 F: F ailure (Liver and Renal failure)</li><li>\u27a4 F: F</li><li>\u27a4 O R MIN: O xygen R eaching the tissues is MIN imum (means hypoxia causing conditions)</li><li>\u27a4 O R MIN: O</li><li>\u27a4 R</li><li>\u27a4 MIN</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "1152b628",
      "audio": ""
    },
    {
      "text": "A 70-year-old hypertensive patient with stage 5 chronic kidney disease was diagnosed recently with Type 2 diabetes mellitus. He does not want to take injectable drugs. Which of the following oral hypoglycemic agents will be preferred in this patient that does not require any dose modification in renal failure?",
      "options": [
        {
          "label": "A",
          "text": "Linagliptin",
          "correct": true
        },
        {
          "label": "B",
          "text": "Vildagliptin",
          "correct": false
        },
        {
          "label": "C",
          "text": "Exenatidie",
          "correct": false
        },
        {
          "label": "D",
          "text": "Metformin",
          "correct": false
        }
      ],
      "correct_answer": "A. Linagliptin",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A. Linagliptin</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Vildagliptin : While vildagliptin is another DPP-4 inhibitor, it requires dose adjustments in patients with renal impairment , making it less ideal than linagliptin for patients with stage 5 CKD .</li><li>\u2022 Option B. Vildagliptin</li><li>\u2022 vildagliptin</li><li>\u2022 DPP-4 inhibitor,</li><li>\u2022 requires dose adjustments</li><li>\u2022 renal impairment</li><li>\u2022 less ideal than linagliptin</li><li>\u2022 stage 5 CKD</li><li>\u2022 Option C. Exenatide : Exenatide is not an oral hypoglycemic agent but an injectable glucagon-like peptide-1 (GLP-1) receptor agonist. It also requires dose adjustments in patients with renal impairment and would not be suitable for a patient who prefers to avoid injectable drugs.</li><li>\u2022 Option C. Exenatide</li><li>\u2022 Exenatide</li><li>\u2022 not</li><li>\u2022 oral hypoglycemic agent</li><li>\u2022 injectable glucagon-like peptide-1 (GLP-1) receptor agonist.</li><li>\u2022 requires dose adjustments</li><li>\u2022 renal impairment</li><li>\u2022 not</li><li>\u2022 Option D. Metformin : Traditionally, metformin has been contraindicated in patients with significant renal impairment due to the risk of lactic acidosis . Although recent guidelines have provided more lenient criteria for its use in patients with moderate renal impairment , it is generally avoided in stage 5 CKD .</li><li>\u2022 Option D. Metformin</li><li>\u2022 metformin</li><li>\u2022 contraindicated in patients</li><li>\u2022 renal impairment due to the risk of lactic acidosis</li><li>\u2022 more lenient criteria</li><li>\u2022 moderate renal impairment</li><li>\u2022 avoided in stage 5 CKD</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Linagliptin, a DPP-4 inhibitor, is a preferred oral hypoglycemic agent for patients with Type 2 diabetes and severe renal impairment , as it does not require dose adjustments in renal failure , simplifying diabetes management in this population.</li><li>\u27a4 Linagliptin, a DPP-4 inhibitor,</li><li>\u27a4 oral hypoglycemic agent</li><li>\u27a4 Type 2 diabetes and severe renal impairment</li><li>\u27a4 does not</li><li>\u27a4 renal failure</li><li>\u27a4 diabetes management</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "35214d72",
      "audio": ""
    },
    {
      "text": "A lady who was treated for breast cancer is on long-term tamoxifen therapy as she is ER-positive. Drug tamoxifen can increase the risk for which of the following cancers?",
      "options": [
        {
          "label": "A",
          "text": "Carcinoma of ovary",
          "correct": false
        },
        {
          "label": "B",
          "text": "Endometrial carcinoma",
          "correct": true
        },
        {
          "label": "C",
          "text": "Breast carcinoma",
          "correct": false
        },
        {
          "label": "D",
          "text": "Chronic myeloid leukemia",
          "correct": false
        }
      ],
      "correct_answer": "B. Endometrial carcinoma",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B. Endometrial carcinoma</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Carcinoma of the ovary: There is no established link between tamoxifen use and an increased risk of ovarian cancer.</li><li>\u2022 Option</li><li>\u2022 A.</li><li>\u2022 Carcinoma of the ovary:</li><li>\u2022 no</li><li>\u2022 tamoxifen use</li><li>\u2022 Option C. Breast carcinoma: Tamoxifen is actually used to reduce the risk of breast cancer recurrence.</li><li>\u2022 Option</li><li>\u2022 C.</li><li>\u2022 Breast carcinoma:</li><li>\u2022 Tamoxifen</li><li>\u2022 reduce the risk of breast cancer</li><li>\u2022 Option D. Chronic myeloid leukemia: There is no evidence to suggest that tamoxifen increases the risk of developing leukemia.</li><li>\u2022 Option</li><li>\u2022 D.</li><li>\u2022 Chronic myeloid leukemia:</li><li>\u2022 no</li><li>\u2022 tamoxifen increases the risk of developing leukemia.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 While tamoxifen is effective in treating and preventing breast cancer recurrence in ER-positive patients by acting as an estrogen antagonist on breast tissue, its agonistic effects on the uterus can increase the risk of endometrial carcinoma, necessitating careful monitoring and evaluation during therapy.</li><li>\u27a4 tamoxifen</li><li>\u27a4 treating and preventing breast cancer</li><li>\u27a4 ER-positive patients</li><li>\u27a4 acting as an estrogen</li><li>\u27a4 antagonist on breast tissue,</li><li>\u27a4 agonistic effects on the uterus</li><li>\u27a4 increase</li><li>\u27a4 endometrial carcinoma,</li><li>\u27a4 careful</li><li>\u27a4 monitoring and evaluation during therapy.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "d01133f8",
      "audio": ""
    },
    {
      "text": "A 52-year-old patient diagnosed with Graves' disease is under consideration for antithyroid therapy. The patient has a history of atrial fibrillation and is currently on beta-blockers. Given the patient's clinical profile and the need to rapidly achieve euthyroidism while minimizing cardiac complications, the healthcare provider is exploring antithyroid medications that can not only reduce thyroid hormone production but also inhibit the peripheral conversion of thyroxine (T4) to the more active triiodothyronine (T3). Which of the following antithyroid medications can inhibit the peripheral conversion of T4 to T3?",
      "options": [
        {
          "label": "A",
          "text": "Carbimazole",
          "correct": false
        },
        {
          "label": "B",
          "text": "Lugol\u2019s iodine",
          "correct": false
        },
        {
          "label": "C",
          "text": "Propylthiouracil",
          "correct": true
        },
        {
          "label": "D",
          "text": "Methimazole",
          "correct": false
        }
      ],
      "correct_answer": "C. Propylthiouracil",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture3.jpg"
      ],
      "explanation": "<p><strong>Ans. C. Propylthiouracil</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Carbimazole : Carbimazole is a pro-drug that is converted to methimazole in the body . It inhibits thyroid hormone synthesis but does not significantly inhibit the peripheral conversion of T4 to T3.</li><li>\u2022 Option A. Carbimazole</li><li>\u2022 pro-drug</li><li>\u2022 converted to methimazole in the body</li><li>\u2022 inhibits thyroid hormone synthesis</li><li>\u2022 does not</li><li>\u2022 inhibit the peripheral conversion of T4 to T3.</li><li>\u2022 Option B. Lugol\u2019s iodine : Lugol's iodine can quickly reduce the size and vascularity of the thyroid gland and inhibit the release of thyroid hormones , but it does not have a direct inhibitory effect on the peripheral conversion of T4 to T3.</li><li>\u2022 Option B. Lugol\u2019s iodine</li><li>\u2022 reduce the size and vascularity of the thyroid gland</li><li>\u2022 inhibit</li><li>\u2022 thyroid hormones</li><li>\u2022 Option D. Methimazole : Methimazole inhibits thyroid hormone synthesis by blocking the iodination of tyrosine residues in thyroglobulin . Like carbimazole , it does not significantly inhibit the peripheral conversion of T4 to T3.</li><li>\u2022 Option D. Methimazole</li><li>\u2022 inhibits thyroid hormone synthesis</li><li>\u2022 iodination of tyrosine</li><li>\u2022 thyroglobulin</li><li>\u2022 carbimazole</li><li>\u2022 does not</li><li>\u2022 inhibit the peripheral conversion of T4 to T3.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "5a77acd1",
      "audio": ""
    },
    {
      "text": "All the following drugs are used in treatment of osteoporosis except.",
      "options": [
        {
          "label": "A",
          "text": "Milnacipran",
          "correct": true
        },
        {
          "label": "B",
          "text": "Teriparatide",
          "correct": false
        },
        {
          "label": "C",
          "text": "Strontium ranelate",
          "correct": false
        },
        {
          "label": "D",
          "text": "Denosumab",
          "correct": false
        }
      ],
      "correct_answer": "A. Milnacipran",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture6.jpg"
      ],
      "explanation": "<p><strong>Ans. A. Milnacipran</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 Option B. Teriparatide : Teriparatide is a recombinant form of parathyroid hormone used in the treatment of osteoporosis. It stimulates new bone formation by acting on osteoblasts , making it effective in reducing the risk of fractures in patients with osteoporosis.</li><li>\u2022 Option B. Teriparatide</li><li>\u2022 recombinant form of parathyroid hormone</li><li>\u2022 osteoporosis.</li><li>\u2022 new bone formation</li><li>\u2022 osteoblasts</li><li>\u2022 reducing the risk of fractures</li><li>\u2022 osteoporosis.</li><li>\u2022 Option C. Strontium ranelate : Strontium ranelate is a medication used to treat severe osteoporosis in postmenopausal women and men at high risk of fractures . It works by simultaneously decreasing bone resorption and increasing bone formation.</li><li>\u2022 Option C. Strontium ranelate</li><li>\u2022 used to treat severe osteoporosis in postmenopausal women</li><li>\u2022 men at high risk of fractures</li><li>\u2022 decreasing bone resorption and increasing bone formation.</li><li>\u2022 Option D. Denosumab : Denosumab is a monoclonal antibody that inhibits RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand) , a protein that acts as the primary signal for bone removal . By inhibiting RANKL, denosumab decreases bone resorption and increases bone mass and strength in patients with osteoporosis.</li><li>\u2022 Option D. Denosumab</li><li>\u2022 monoclonal antibody that inhibits RANKL (Receptor Activator of Nuclear Factor Kappa-B</li><li>\u2022 Ligand)</li><li>\u2022 acts</li><li>\u2022 primary signal for bone removal</li><li>\u2022 By inhibiting RANKL,</li><li>\u2022 decreases bone resorption and</li><li>\u2022 increases bone mass and strength</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Drugs Used for Osteoporosis</li><li>\u27a4 Drugs Used for Osteoporosis</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "5add4a11",
      "audio": ""
    },
    {
      "text": "Octreotide is used in all except?",
      "options": [
        {
          "label": "A",
          "text": "Glucagonoma",
          "correct": false
        },
        {
          "label": "B",
          "text": "Insulinoma",
          "correct": false
        },
        {
          "label": "C",
          "text": "Carcinoid syndrome",
          "correct": false
        },
        {
          "label": "D",
          "text": "Glioma",
          "correct": true
        }
      ],
      "correct_answer": "D. Glioma",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture8.jpg"
      ],
      "explanation": "<p><strong>Ans. D. Glioma</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Glucagonoma : Octreotide is used in the management of glucagonoma, a rare type of pancreatic neuroendocrine tumor that secretes excessive amounts of glucagon. Octreotide helps in controlling symptoms by inhibiting glucagon secretion.</li><li>\u2022 Option A. Glucagonoma</li><li>\u2022 Octreotide</li><li>\u2022 glucagonoma,</li><li>\u2022 pancreatic neuroendocrine tumor</li><li>\u2022 secretes excessive amounts of glucagon.</li><li>\u2022 inhibiting glucagon secretion.</li><li>\u2022 Option B. Insulinoma : Although insulinomas produce excessive insulin, octreotide can sometimes be used in the management of these tumors to help control hypoglycemia , particularly in patients with metastatic disease or those who are not candidates for surgery.</li><li>\u2022 Option B. Insulinoma</li><li>\u2022 insulinomas produce excessive insulin,</li><li>\u2022 octreotide</li><li>\u2022 help control hypoglycemia</li><li>\u2022 metastatic disease</li><li>\u2022 not candidates for</li><li>\u2022 surgery.</li><li>\u2022 Option C. Carcinoid syndrome : Octreotide is effectively used in the treatment of carcinoid syndrome , which is characterized by flushing, diarrhea, and wheezing due to the secretion of serotonin and other vasoactive substances by carcinoid tumors. Octreotide helps in reducing these symptoms by inhibiting the secretion of these substances.</li><li>\u2022 Option C. Carcinoid syndrome</li><li>\u2022 Octreotide</li><li>\u2022 carcinoid syndrome</li><li>\u2022 flushing, diarrhea, and wheezing</li><li>\u2022 secretion of serotonin</li><li>\u2022 vasoactive substances</li><li>\u2022 carcinoid tumors.</li><li>\u2022 Octreotide</li><li>\u2022 inhibiting the secretion of these substances.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Uses of Octreotide</li><li>\u27a4 Uses of Octreotide</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "9d61014a",
      "audio": ""
    },
    {
      "text": "All the following statements about octreotide are true except.",
      "options": [
        {
          "label": "A",
          "text": "It is effective orally.",
          "correct": true
        },
        {
          "label": "B",
          "text": "It is used for the treatment of acromegaly.",
          "correct": false
        },
        {
          "label": "C",
          "text": "It can be used for the management of secretory Diarrhea.",
          "correct": false
        },
        {
          "label": "D",
          "text": "It can be used in portal hypertension.",
          "correct": false
        }
      ],
      "correct_answer": "A. It is effective orally.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A. It is effective orally.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. It is used for the treatment of acromegaly : This statement is true . Octreotide is used in the treatment of acromegaly, a condition characterized by excessive growth hormone production, leading to enlarged features. Octreotide helps by inhibiting growth hormone secretion.</li><li>\u2022 Option B. It is used for the treatment of acromegaly</li><li>\u2022 true</li><li>\u2022 Octreotide</li><li>\u2022 treatment of acromegaly,</li><li>\u2022 excessive growth hormone production, leading to enlarged</li><li>\u2022 Octreotide</li><li>\u2022 inhibiting</li><li>\u2022 growth hormone secretion.</li><li>\u2022 Option C. It can be used for the management of secretory Diarrhea : This is also true. Octreotide can manage secretory diarrhea, including that caused by certain tumors (like carcinoid tumors or VIPomas), by inhibiting the secretion of various gastrointestinal hormones and substances.</li><li>\u2022 Option C. It can be used for the management of secretory Diarrhea</li><li>\u2022 true.</li><li>\u2022 secretory diarrhea,</li><li>\u2022 caused by certain tumors (like carcinoid tumors or VIPomas),</li><li>\u2022 inhibiting the secretion</li><li>\u2022 hormones and substances.</li><li>\u2022 Option D. It can be used in portal hypertension : True. Octreotide is used in the management of portal hypertension, particularly to control variceal bleeding, by reducing blood flow to the gastrointestinal tract and lowering portal vein pressure.</li><li>\u2022 Option D. It can be used in portal hypertension</li><li>\u2022 True.</li><li>\u2022 portal hypertension,</li><li>\u2022 control variceal bleeding,</li><li>\u2022 reducing blood flow</li><li>\u2022 gastrointestinal tract</li><li>\u2022 lowering portal vein pressure.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 While octreotide is a valuable medication in the management of acromegaly, secretory diarrhea, and portal hypertension, it must be administered through parenteral routes due to its poor oral bioavailability.</li><li>\u27a4 octreotide</li><li>\u27a4 acromegaly, secretory diarrhea, and portal hypertension,</li><li>\u27a4 parenteral routes</li><li>\u27a4 poor oral bioavailability.</li><li>\u27a4 Note - You can remember this fact from the name of the drug. If the name of a drug ends with \u2018tide\u2019, it is a peptide and peptides cannot be given orally because, the presence of peptidases (like pepsin, trypsin etc.) will make these inactive.</li><li>\u27a4 Note</li><li>\u27a4 name of a drug ends with \u2018tide\u2019,</li><li>\u27a4 peptide and peptides</li><li>\u27a4 cannot be given orally</li><li>\u27a4 presence of peptidases (like pepsin, trypsin etc.)</li><li>\u27a4 inactive.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "8658993b",
      "audio": ""
    },
    {
      "text": "Ulipristal is a relatively new drug being used by gynecologists. It acts as a?",
      "options": [
        {
          "label": "A",
          "text": "GnRH agonist",
          "correct": false
        },
        {
          "label": "B",
          "text": "Androgen antagonist",
          "correct": false
        },
        {
          "label": "C",
          "text": "Selective estrogen receptor modulator",
          "correct": false
        },
        {
          "label": "D",
          "text": "Selective progesterone receptor modulator",
          "correct": true
        }
      ],
      "correct_answer": "D. Selective progesterone receptor modulator",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D. Selective progesterone receptor modulator</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. GnRH agonist : GnRH agonists work by initially stimulating and then downregulating the production of gonadotropins (LH and FSH) , leading to a decrease in estrogen and testosterone production . Examples include leuprolide and goserelin . Ulipristal does not act through this mechanism.</li><li>\u2022 Option A. GnRH agonist</li><li>\u2022 initially stimulating and then downregulating the production of gonadotropins (LH</li><li>\u2022 and FSH)</li><li>\u2022 decrease in estrogen and testosterone production</li><li>\u2022 leuprolide and goserelin</li><li>\u2022 Ulipristal does</li><li>\u2022 not act</li><li>\u2022 mechanism.</li><li>\u2022 Option B. Androgen antagonist : Androgen antagonists block the effects of androgens (male hormones) at their receptor sites . They are used in conditions like prostate cancer and hirsutism in women. Ulipristal does not function as an androgen antagonist.</li><li>\u2022 Option B. Androgen antagonist</li><li>\u2022 block the effects of androgens (male hormones) at their receptor sites</li><li>\u2022 prostate cancer and hirsutism in women.</li><li>\u2022 Option C. Selective estrogen receptor modulator : SERMs, such as tamoxifen or raloxifene, act on estrogen receptors , having agonistic or antagonistic effects depending on the target tissue . Ulipristal, however, specifically modulates progesterone receptors, not estrogen receptors.</li><li>\u2022 Option C. Selective estrogen receptor modulator</li><li>\u2022 tamoxifen or raloxifene,</li><li>\u2022 estrogen receptors</li><li>\u2022 agonistic or antagonistic effects depending on the target tissue</li><li>\u2022 Ulipristal,</li><li>\u2022 modulates progesterone receptors,</li><li>\u2022 not</li><li>\u2022 estrogen receptors.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Ulipristal is a selective progesterone receptor modulator (SPRM) used in gynecology for emergency contraception and the treatment of uterine fibroids . Its unique action on progesterone receptors allows for versatile therapeutic effects in reproductive health.</li><li>\u27a4 Ulipristal</li><li>\u27a4 selective progesterone receptor modulator (SPRM)</li><li>\u27a4 gynecology for emergency contraception</li><li>\u27a4 uterine fibroids</li><li>\u27a4 action on progesterone receptors</li><li>\u27a4 versatile therapeutic effects</li><li>\u27a4 reproductive</li><li>\u27a4 health.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "de19c9a5",
      "audio": ""
    },
    {
      "text": "What are the appropriate instructions to be given while prescribing bisphosphonates to a patient?",
      "options": [
        {
          "label": "A",
          "text": "To be given an empty stomach with a full glass of water.",
          "correct": true
        },
        {
          "label": "B",
          "text": "Must be taken along with food.",
          "correct": false
        },
        {
          "label": "C",
          "text": "Should be stopped if features of gastritis develop.",
          "correct": false
        },
        {
          "label": "D",
          "text": "Should be stopped if bone pains occur.",
          "correct": false
        }
      ],
      "correct_answer": "A. To be given an empty stomach with a full glass of water.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A. To be given empty stomach with a glass of water</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Must be taken along with food : This instruction is incorrect because food significantly decreases the absorption of bisphosphonates. They should be taken on an empty stomach.</li><li>\u2022 Option B. Must be taken along with food</li><li>\u2022 incorrect</li><li>\u2022 food</li><li>\u2022 decreases the absorption of</li><li>\u2022 bisphosphonates.</li><li>\u2022 should be taken</li><li>\u2022 empty stomach.</li><li>\u2022 Option C. Should be stopped if features of gastritis develop : While patients should report any severe gastrointestinal symptoms to their healthcare provider, the decision to stop the medication should be made by the physician. Management strategies may include evaluating the patient's condition, considering an alternative bisphosphonate formulation (e.g., intravenous), or addressing the gastritis while continuing treatment as necessary.</li><li>\u2022 Option C. Should be stopped if features of gastritis develop</li><li>\u2022 severe gastrointestinal symptoms</li><li>\u2022 healthcare provider,</li><li>\u2022 decision to stop</li><li>\u2022 by the physician.</li><li>\u2022 alternative bisphosphonate formulation (e.g., intravenous),</li><li>\u2022 addressing</li><li>\u2022 gastritis</li><li>\u2022 continuing treatment as necessary.</li><li>\u2022 Option D. Should be stopped if bone pains occur : Bone pain can be a side effect of bisphosphonates, but patients should consult their healthcare provider before stopping the medication . The provider may assess the cause of bone pain and consider alternative treatments or supportive measures rather than immediately discontinuing the bisphosphonate.</li><li>\u2022 Option D. Should be stopped if bone pains occur</li><li>\u2022 side effect of bisphosphonates,</li><li>\u2022 should consult</li><li>\u2022 healthcare provider</li><li>\u2022 stopping the medication</li><li>\u2022 cause of bone pain</li><li>\u2022 alternative</li><li>\u2022 treatments or supportive</li><li>\u2022 immediately discontinuing the bisphosphonate.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 When prescribing bisphosphonates, it is crucial to instruct patients to take the medication on an empty stomach with plenty of water and to remain upright for at least 30 to 60 minutes afterward to prevent gastrointestinal complications and ensure optimal absorption of the drug.</li><li>\u27a4 bisphosphonates,</li><li>\u27a4 crucial to instruct patients</li><li>\u27a4 empty stomach</li><li>\u27a4 plenty of</li><li>\u27a4 water</li><li>\u27a4 upright for</li><li>\u27a4 least 30 to 60 minutes</li><li>\u27a4 prevent gastrointestinal complications</li><li>\u27a4 optimal</li><li>\u27a4 absorption of the drug.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "052d9960",
      "audio": ""
    },
    {
      "text": "A patient of diabetes mellitus and hypertension is admitted in the hospital with features of sepsis and there is increase in serum creatinine levels. Which of the following drugs should be stopped?",
      "options": [
        {
          "label": "A",
          "text": "Metformin",
          "correct": true
        },
        {
          "label": "B",
          "text": "Insulin",
          "correct": false
        },
        {
          "label": "C",
          "text": "Metoprolol",
          "correct": false
        },
        {
          "label": "D",
          "text": "Linagliptin",
          "correct": false
        }
      ],
      "correct_answer": "A. Metformin",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A. Metformin</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Insulin : Insulin may still be needed to manage the patient' s blood glucose levels, especially in the stress of sepsis , which can cause hyperglycemia.</li><li>\u2022 Option B. Insulin</li><li>\u2022 s blood glucose levels,</li><li>\u2022 stress of sepsis</li><li>\u2022 hyperglycemia.</li><li>\u2022 Option C. Metoprolol : It is a lipid soluble beta-blocker used to manage hypertension and other cardiovascular conditions . It is safe in renal failure . Beta blockers which should be avoided in renal failure are atenolol, nadolol and sotalol (ANS)</li><li>\u2022 Option C. Metoprolol</li><li>\u2022 lipid soluble beta-blocker</li><li>\u2022 hypertension</li><li>\u2022 cardiovascular conditions</li><li>\u2022 safe</li><li>\u2022 renal failure</li><li>\u2022 Beta blockers</li><li>\u2022 avoided in renal failure are atenolol, nadolol and sotalol (ANS)</li><li>\u2022 Option D. Linagliptin : A DPP-4 inhibitor used in the management of type 2 diabetes. It is considered safe in patients with renal impairment unlike other drugs in this group.</li><li>\u2022 Option D. Linagliptin</li><li>\u2022 DPP-4 inhibitor</li><li>\u2022 type 2 diabetes.</li><li>\u2022 renal impairment</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 In patients with diabetes and renal impairment, especially in acute settings such as sepsis, metformin should be discontinued to prevent the risk of lactic acidosis. It is important to monitor renal function closely and adjust medication as needed based on the patient\u2019s current health status.</li><li>\u27a4 diabetes and renal impairment,</li><li>\u27a4 acute settings such as sepsis,</li><li>\u27a4 metformin</li><li>\u27a4 risk of lactic acidosis.</li><li>\u27a4 monitor renal function</li><li>\u27a4 current health status.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "6c3ce945",
      "audio": ""
    },
    {
      "text": "Longest acting insulin among the following is?",
      "options": [
        {
          "label": "A",
          "text": "Neutral protamine Hagedorn",
          "correct": false
        },
        {
          "label": "B",
          "text": "Insulin glulisine",
          "correct": false
        },
        {
          "label": "C",
          "text": "Insulin glargine",
          "correct": true
        },
        {
          "label": "D",
          "text": "Lente insulin",
          "correct": false
        }
      ],
      "correct_answer": "C. Insulin glargine",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture15.jpg"
      ],
      "explanation": "<p><strong>Ans. C. Insulin glargine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Neutral protamine Hagedorn (NPH) : NPH insulin is an intermediate-acting insulin with a duration of action that typically ranges from 16 to 24 hours . While it does provide longer coverage than short-acting insulins, it does not last as long as insulin glargine.</li><li>\u2022 Option A. Neutral protamine Hagedorn (NPH)</li><li>\u2022 intermediate-acting insulin</li><li>\u2022 duration of action</li><li>\u2022 16 to 24 hours</li><li>\u2022 longer coverage than short-acting insulins,</li><li>\u2022 Option B. Insulin glulisine : Insulin glulisine is a rapid-acting insulin analog with a quick onset of action (approximately 15 minutes ) and a shorter duration of action (3 to 5 hours) , making it well-suited for controlling blood sugar levels during meals.</li><li>\u2022 Option B. Insulin glulisine</li><li>\u2022 rapid-acting insulin analog</li><li>\u2022 quick onset of action</li><li>\u2022 15 minutes</li><li>\u2022 shorter duration of action (3 to 5 hours)</li><li>\u2022 well-suited for controlling blood sugar levels during meals.</li><li>\u2022 Option D. Lente insulin : Lente insulin is an intermediate-acting insulin with a duration of action similar to NPH insulin. It is not as long-acting as insulin glargine.</li><li>\u2022 Option D. Lente insulin</li><li>\u2022 intermediate-acting insulin</li><li>\u2022 duration of action</li><li>\u2022 NPH insulin.</li><li>\u2022 not</li><li>\u2022 long-acting as insulin glargine.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 INSULIN PREPARATIONS</li><li>\u27a4 INSULIN PREPARATIONS</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "99b5f5d2",
      "audio": ""
    },
    {
      "text": "A patient presented with swelling in the neck as shown in figure. She also complained of decreased appetite, fatigue, cold intolerance, and menstrual irregularities. She gained 10 kg weight in the last 4-5 months. Thyroid function tests showed normal T4 levels but elevated TSH levels. The patient should be treated with.",
      "options": [
        {
          "label": "A",
          "text": "Liothyronine",
          "correct": false
        },
        {
          "label": "B",
          "text": "L-Thyroxine",
          "correct": true
        },
        {
          "label": "C",
          "text": "Carbimazole",
          "correct": false
        },
        {
          "label": "D",
          "text": "Steroids",
          "correct": false
        }
      ],
      "correct_answer": "B. L-Thyroxine",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture22.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B. L-Thyroxine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Liothyronine : Liothyronine is a synthetic form of triiodothyronine (T3) . While it can be used in certain specific situations, such as in combination therapy with levothyroxine for some patients, L-Thyroxine remains the primary treatment for hypothyroidism due to its stability, longer half-life, and more consistent serum levels.</li><li>\u2022 Option A. Liothyronine</li><li>\u2022 synthetic form of triiodothyronine (T3)</li><li>\u2022 used</li><li>\u2022 specific situations,</li><li>\u2022 combination therapy with levothyroxine</li><li>\u2022 L-Thyroxine</li><li>\u2022 primary treatment</li><li>\u2022 hypothyroidism</li><li>\u2022 stability, longer half-life, and more consistent serum levels.</li><li>\u2022 Option C. Carbimazole : Carbimazole is used to treat hyperthyroidism, not hypothyroidism. It works by inhibiting the synthesis of thyroid hormones, which would be contraindicated in a patient already showing signs of low thyroid hormone activity.</li><li>\u2022 Option C. Carbimazole</li><li>\u2022 treat hyperthyroidism,</li><li>\u2022 inhibiting the synthesis of</li><li>\u2022 thyroid hormones,</li><li>\u2022 contraindicated in a patient</li><li>\u2022 signs of low thyroid hormone activity.</li><li>\u2022 Option D. Steroids : Steroids are not a primary treatment for primary hypothyroidism . They can be used in specific cases of t hyroiditis where inflammation is a significant component, but they would not be the first choice i n typical hypothyroidism treatment.</li><li>\u2022 Option D. Steroids</li><li>\u2022 not a primary treatment for primary hypothyroidism</li><li>\u2022 specific cases of</li><li>\u2022 hyroiditis</li><li>\u2022 inflammation is a significant</li><li>\u2022 not be the first choice i</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 In a patient with hypothyroidism indicated by symptoms of thyroid hormone deficiency and elevated TSH levels with normal T4, L-Thyroxine is the appropriate treatment to normalize thyroid function and alleviate symptoms.</li><li>\u27a4 hypothyroidism</li><li>\u27a4 thyroid hormone deficiency</li><li>\u27a4 elevated TSH levels</li><li>\u27a4 normal T4, L-Thyroxine</li><li>\u27a4 treatment</li><li>\u27a4 normalize thyroid function and alleviate symptoms.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "aba1ad01",
      "audio": ""
    },
    {
      "text": "A 58-year-old female with a history of type 2 diabetes mellitus presents to the clinic with complaints of recurrent urinary tract infections (UTIs) over the past few months. She reports symptoms of urgency, frequency, and dysuria. Her diabetes has been managed with an antidiabetic medication added to her regimen about 6 months ago, around the time the UTIs started becoming more frequent. Her medical history is otherwise unremarkable, and she is not on any other new medications. Which of the following drugs in her treatment regimen is most likely implicated in causing this adverse effect?",
      "options": [
        {
          "label": "A",
          "text": "Sitagliptin",
          "correct": false
        },
        {
          "label": "B",
          "text": "Dapagliflozin",
          "correct": true
        },
        {
          "label": "C",
          "text": "Linagliptin",
          "correct": false
        },
        {
          "label": "D",
          "text": "Pramlintide",
          "correct": false
        }
      ],
      "correct_answer": "B. Dapagliflozin",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B. Dapagliflozin</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Sitagliptin and C. Linagliptin : Both are Dipeptidyl peptidase-4 (DPP-4) inhibitors. They work by increasing incretin levels, which inhibit glucagon release and increase insulin secretion . DPP-4 inhibitors are not commonly associated with an increased risk of UTIs.</li><li>\u2022 Option A. Sitagliptin</li><li>\u2022 C. Linagliptin</li><li>\u2022 Dipeptidyl peptidase-4 (DPP-4) inhibitors.</li><li>\u2022 increasing incretin levels,</li><li>\u2022 inhibit glucagon release and increase insulin secretion</li><li>\u2022 not</li><li>\u2022 increased risk</li><li>\u2022 of UTIs.</li><li>\u2022 Option D. Pramlintide : An amylin analogue used in addition to insulin therapy in type 1 and type 2 diabetes to improve glycemic control. Pramlintide is not associated with an increased risk of UTIs.</li><li>\u2022 Option D. Pramlintide</li><li>\u2022 amylin analogue</li><li>\u2022 insulin therapy in type 1 and type 2 diabetes</li><li>\u2022 glycemic</li><li>\u2022 Pramlintide</li><li>\u2022 not</li><li>\u2022 increased risk of UTIs.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Dapagliflozin is an SGLT2 inhibitor that can increase the risk of urinary tract infections due to glucosuria, which can encourage bacterial growth in the urinary tract. Important points about SGLT2 Inhibitors are -</li><li>\u27a4 Dapagliflozin is an SGLT2 inhibitor</li><li>\u27a4 increase the risk of urinary tract infections</li><li>\u27a4 glucosuria,</li><li>\u27a4 bacterial growth</li><li>\u27a4 Important points about SGLT2 Inhibitors are -</li><li>\u27a4 These reduce reabsorption of filtered glucose and lowers the renal threshold for glucose , and thereby increases urinary glucose excretion. These are NOT recommended for patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. These should NOT be initiated in patients with an eGFR less than 60 mL/min/1 .73 m 2. Adverse Effects: Increases the risk of genital mycotic infections. Urinary tract infections. Hypotension. I mpairment in Renal Function. Increases in Low-Density Lipoprotein Cholesterol (LDL-C)</li><li>\u27a4 These reduce reabsorption of filtered glucose and lowers the renal threshold for glucose , and thereby increases urinary glucose excretion.</li><li>\u27a4 reduce reabsorption of filtered glucose</li><li>\u27a4 lowers the renal threshold for glucose</li><li>\u27a4 increases urinary</li><li>\u27a4 glucose excretion.</li><li>\u27a4 These are NOT recommended for patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.</li><li>\u27a4 NOT</li><li>\u27a4 type 1 diabetes mellitus</li><li>\u27a4 diabetic ketoacidosis.</li><li>\u27a4 These should NOT be initiated in patients with an eGFR less than 60 mL/min/1 .73 m 2.</li><li>\u27a4 NOT</li><li>\u27a4 eGFR less than 60 mL/min/1 .73 m 2.</li><li>\u27a4 Adverse Effects: Increases the risk of genital mycotic infections. Urinary tract infections. Hypotension. I mpairment in Renal Function. Increases in Low-Density Lipoprotein Cholesterol (LDL-C)</li><li>\u27a4 Increases the risk of genital mycotic infections. Urinary tract infections. Hypotension. I mpairment in Renal Function. Increases in Low-Density Lipoprotein Cholesterol (LDL-C)</li><li>\u27a4 Increases the risk of genital mycotic infections.</li><li>\u27a4 Increases</li><li>\u27a4 genital mycotic infections.</li><li>\u27a4 Urinary tract infections.</li><li>\u27a4 Urinary tract infections.</li><li>\u27a4 Hypotension.</li><li>\u27a4 Hypotension.</li><li>\u27a4 I mpairment in Renal Function.</li><li>\u27a4 mpairment in Renal Function.</li><li>\u27a4 Increases in Low-Density Lipoprotein Cholesterol (LDL-C)</li><li>\u27a4 Increases in Low-Density Lipoprotein Cholesterol (LDL-C)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "33627ac7",
      "audio": ""
    },
    {
      "text": "Non-pulsatile administration of GnRH agonist can be used in all of the following conditions except.",
      "options": [
        {
          "label": "A",
          "text": "Endometriosis",
          "correct": false
        },
        {
          "label": "B",
          "text": "Male infertility",
          "correct": true
        },
        {
          "label": "C",
          "text": "Precocious puberty",
          "correct": false
        },
        {
          "label": "D",
          "text": "Prostatic carcinoma",
          "correct": false
        }
      ],
      "correct_answer": "B. Male infertility",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B. Male infertility</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Endometriosis : Continuous GnRH agonist treatment can suppress ovarian function and is beneficial in conditions like endometriosis.</li><li>\u2022 Option A.</li><li>\u2022 Endometriosis</li><li>\u2022 Continuous GnRH agonist</li><li>\u2022 suppress ovarian function</li><li>\u2022 endometriosis.</li><li>\u2022 Option C. Precocious Puberty : GnRH agonists are used to suppress premature gonadotropin secretion in children with central precocious puberty.</li><li>\u2022 Option C.</li><li>\u2022 Precocious Puberty</li><li>\u2022 GnRH agonists</li><li>\u2022 premature gonadotropin secretion</li><li>\u2022 central</li><li>\u2022 precocious puberty.</li><li>\u2022 Option D. Prostatic Carcinoma : In men with advanced prostate cancer, continuous GnRH agonist treatment is used to suppress androgen production.</li><li>\u2022 Option D.</li><li>\u2022 Prostatic Carcinoma</li><li>\u2022 advanced prostate cancer,</li><li>\u2022 GnRH agonist</li><li>\u2022 suppress</li><li>\u2022 androgen production.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Non-pulsatile administration of GnRH agonists is utilized for conditions requiring suppression of gonadotropin secretion , such as endometriosis, prostatic carcinoma, and precocious puberty, but not for male infertility , which requires pulsatile treatment to stimulate gonadotropin release.</li><li>\u27a4 Non-pulsatile administration of GnRH agonists</li><li>\u27a4 suppression of gonadotropin secretion</li><li>\u27a4 endometriosis, prostatic carcinoma, and precocious puberty,</li><li>\u27a4 not</li><li>\u27a4 male infertility</li><li>\u27a4 pulsatile treatment</li><li>\u27a4 gonadotropin release.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "1d088f05",
      "audio": ""
    },
    {
      "text": "Which of the following drug is approved for treatment of type 1 as well as type 2 diabetes mellitus?",
      "options": [
        {
          "label": "A",
          "text": "Pramlintide",
          "correct": true
        },
        {
          "label": "B",
          "text": "Metformin",
          "correct": false
        },
        {
          "label": "C",
          "text": "Sitagliptin",
          "correct": false
        },
        {
          "label": "D",
          "text": "Glipizide",
          "correct": false
        }
      ],
      "correct_answer": "A. Pramlintide",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A. Pramlintide</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Metformin : Primarily used in the treatment of type 2 diabetes mellitus, metformin is a biguanide that reduces hepatic glucose production and improves insulin sensitivity. It is not used in the treatment of type 1 diabetes because type 1 diabetes involves insulin deficiency, and metformin does not replace insulin.</li><li>\u2022 Option B. Metformin</li><li>\u2022 type 2 diabetes mellitus,</li><li>\u2022 biguanide</li><li>\u2022 reduces hepatic</li><li>\u2022 glucose production and improves insulin sensitivity.</li><li>\u2022 not used</li><li>\u2022 type 1 diabetes</li><li>\u2022 insulin deficiency,</li><li>\u2022 metformin does not replace insulin.</li><li>\u2022 Option C. Sitagliptin : A dipeptidyl peptidase-4 (DPP-4) inhibitor used in the treatment of type 2 diabetes . It works by increasing incretin levels , which inhibit glucagon release and increase insulin secretion in a glucose-dependent manner. Sitagliptin is not approved for use in type 1 diabetes.</li><li>\u2022 Option C. Sitagliptin</li><li>\u2022 dipeptidyl peptidase-4 (DPP-4) inhibitor</li><li>\u2022 type 2 diabetes</li><li>\u2022 increasing</li><li>\u2022 incretin levels</li><li>\u2022 inhibit glucagon release and increase insulin secretion</li><li>\u2022 glucose-dependent</li><li>\u2022 Sitagliptin</li><li>\u2022 not</li><li>\u2022 type 1 diabetes.</li><li>\u2022 Option D. Glipizide : A sulfonylurea used in the treatment of type 2 diabetes . It stimulates the release of insulin from pancreatic \u03b2-cells . Because individuals with type 1 diabetes have little to no insulin production, sulfonylureas like glipizide are not effective for type 1 diabetes.</li><li>\u2022 Option D. Glipizide</li><li>\u2022 sulfonylurea</li><li>\u2022 type 2 diabetes</li><li>\u2022 release of insulin from pancreatic \u03b2-cells</li><li>\u2022 type 1 diabetes</li><li>\u2022 no insulin production, sulfonylureas like glipizide</li><li>\u2022 type 1 diabetes.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Pramlintide is approved for both type 1 and type 2 diabetes as an adjunct to insulin therapy due to its role in modulating gastric emptying and blood glucose levels post meals.</li><li>\u27a4 Pramlintide</li><li>\u27a4 both type 1 and type 2 diabetes</li><li>\u27a4 adjunct to insulin therapy</li><li>\u27a4 modulating gastric</li><li>\u27a4 emptying and blood glucose levels post meals.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "043b0514",
      "audio": ""
    },
    {
      "text": "All the following agents are correctly paired with an appropriate clinical use of the drug except.",
      "options": [
        {
          "label": "A",
          "text": "Desmopressin: Treatment of diabetes insipidus.",
          "correct": false
        },
        {
          "label": "B",
          "text": "Octreotide: Treatment of bleeding esophageal varices.",
          "correct": false
        },
        {
          "label": "C",
          "text": "Oxytocin: Induction of labor.",
          "correct": false
        },
        {
          "label": "D",
          "text": "Goserelin: Growth hormone deficiency",
          "correct": true
        }
      ],
      "correct_answer": "D. Goserelin: Growth hormone deficiency",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D. Goserelin: Growth hormone deficiency</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Desmopressin: Desmopressin is a synthetic analogue of vasopressin and is drug of choice for the treatment of central diabetes insipidus and nocturnal enuresis. It is also used for managing bleeding in patients with von Willebrand disease and mild hemophilia A due to its ability to increase the levels of von Willebrand factor and factor VIII .</li><li>\u2022 Option A. Desmopressin:</li><li>\u2022 synthetic analogue of vasopressin</li><li>\u2022 central</li><li>\u2022 diabetes insipidus and nocturnal enuresis.</li><li>\u2022 bleeding</li><li>\u2022 with von Willebrand disease and mild hemophilia A</li><li>\u2022 increase the levels of von Willebrand factor and factor VIII</li><li>\u2022 Option B. Octreotide: Octreotide is a somatostatin analogue that can reduce portal blood flow and is used in the management of bleeding esophageal varices as an adjunct to specific treatments like endoscopic band ligation or sclerotherapy.</li><li>\u2022 Option B. Octreotide:</li><li>\u2022 somatostatin analogue</li><li>\u2022 reduce portal blood flow</li><li>\u2022 used</li><li>\u2022 bleeding esophageal varices</li><li>\u2022 endoscopic band ligation or sclerotherapy.</li><li>\u2022 Option C. Oxytocin: Oxytocin is a peptide hormone and is drug of choice to induce labor in pregnant women who are at or near term when there is a medical reason for inducing labor, or to strengthen labor contractions during childbirth.</li><li>\u2022 Option C. Oxytocin:</li><li>\u2022 peptide hormone</li><li>\u2022 drug of choice</li><li>\u2022 induce labor in pregnant women</li><li>\u2022 at or near</li><li>\u2022 inducing labor, or to strengthen labor contractions during childbirth.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Goserelin is a GnRH agonist used primarily in the treatment of hormone-sensitive cancers and is not indicated for growth hormone deficiency, which would require growth hormone therapy or other specific treatments related to growth hormone biosynthesis or action.</li><li>\u27a4 Goserelin</li><li>\u27a4 GnRH agonist</li><li>\u27a4 hormone-sensitive cancers</li><li>\u27a4 not indicated for growth hormone</li><li>\u27a4 deficiency,</li><li>\u27a4 growth hormone therapy</li><li>\u27a4 specific treatments</li><li>\u27a4 growth hormone biosynthesis or</li><li>\u27a4 action.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "7a531079",
      "audio": ""
    },
    {
      "text": "Long term steroid therapy can lead to suppression of hypothalamic pituitary-adrenal axis. It can be overcome by using alternate day therapy with corticosteroids. Which of the following steroids is unsuitable for alternate day therapy for such purpose?",
      "options": [
        {
          "label": "A",
          "text": "Cortisol",
          "correct": false
        },
        {
          "label": "B",
          "text": "Prednisolone",
          "correct": false
        },
        {
          "label": "C",
          "text": "Betamethasone",
          "correct": true
        },
        {
          "label": "D",
          "text": "Hydrocortisone",
          "correct": false
        }
      ],
      "correct_answer": "C. Betamethasone",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C. Betamethasone</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Cortisol: Cortisol, also known as hydrocortisone when used as a medication, has a short duration of action, making it suitable for alternate day therapy.</li><li>\u2022 Option A. Cortisol:</li><li>\u2022 Cortisol,</li><li>\u2022 hydrocortisone</li><li>\u2022 short duration of action,</li><li>\u2022 alternate day therapy.</li><li>\u2022 Option B. Prednisolone: Prednisolone is an intermediate-acting corticosteroid that is commonly used in alternate day therapy to reduce HPA axis suppression.</li><li>\u2022 Option B. Prednisolone:</li><li>\u2022 intermediate-acting corticosteroid</li><li>\u2022 alternate day therapy to</li><li>\u2022 reduce HPA axis suppression.</li><li>\u2022 Option D. Hydrocortisone: Hydrocortisone is essentially synthetic cortisol with a short duration of action , suitable for alternate day therapy to minimize HPA axis suppression.</li><li>\u2022 Option D. Hydrocortisone:</li><li>\u2022 essentially synthetic cortisol</li><li>\u2022 short duration of action</li><li>\u2022 alternate day</li><li>\u2022 minimize HPA axis suppression.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Betamethasone's long duration of action makes it inappropriate for alternate day therapy designed to mitigate HPA axis suppression, unlike shorter-acting steroids like hydrocortisone , which are better suited for such treatment schedules.</li><li>\u27a4 Betamethasone's long duration of action</li><li>\u27a4 alternate day therapy</li><li>\u27a4 mitigate HPA axis</li><li>\u27a4 suppression,</li><li>\u27a4 shorter-acting steroids like hydrocortisone</li><li>\u27a4 better</li><li>\u27a4 treatment schedules.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "73688ff0",
      "audio": ""
    },
    {
      "text": "All the following statements are true except.",
      "options": [
        {
          "label": "A",
          "text": "Terlipressin is preferred over desmopressin for treatment of bleeding esophageal varices.",
          "correct": false
        },
        {
          "label": "B",
          "text": "Desmopressin is not useful for treatment of nephrogenic diabetes insipidus.",
          "correct": false
        },
        {
          "label": "C",
          "text": "Amiloride is used for treatment of lithium induced diabetes insipidus.",
          "correct": false
        },
        {
          "label": "D",
          "text": "Desmopressin can be used for treatment of both pituitary and renal diabetes insipidus.",
          "correct": true
        }
      ],
      "correct_answer": "D. Desmopressin can be used for treatment of both pituitary and renal diabetes insipidus.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D. Desmopressin can be used for treatment of both pituitary and renal diabetes insipidus.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Terlipressin is preferred over desmopressin for treatment of bleeding esophageal varices: True. Terlipressin, a synthetic analogue of vasopressin with V1 agonistic action, reduces portal pressure and is preferred in the treatment of esophageal variceal bleeding due to its longer activity and fewer side effects.</li><li>\u2022 Option A. Terlipressin is preferred over desmopressin for treatment of bleeding esophageal varices:</li><li>\u2022 True.</li><li>\u2022 synthetic</li><li>\u2022 analogue of vasopressin</li><li>\u2022 V1 agonistic</li><li>\u2022 reduces portal pressure</li><li>\u2022 treatment of esophageal variceal bleeding</li><li>\u2022 longer activity and fewer side effects.</li><li>\u2022 Option B. Desmopressin is not useful for treatment of nephrogenic diabetes insipidus: True. Desmopressin is ineffective in nephrogenic DI because the kidney does not respond to ADH.</li><li>\u2022 Option B. Desmopressin is not useful for treatment of nephrogenic diabetes insipidus:</li><li>\u2022 True.</li><li>\u2022 ineffective</li><li>\u2022 nephrogenic DI</li><li>\u2022 kidney does not respond to ADH.</li><li>\u2022 Option C. Amiloride is used for treatment of lithium induced diabetes insipidus: True . Amiloride blocks the entry of lithium ions through sodium channels in the collecting duct cells , effectively mitigating the diabetes insip idus induced by lithium.</li><li>\u2022 Option C. Amiloride is used for treatment of lithium induced diabetes insipidus:</li><li>\u2022 True</li><li>\u2022 blocks</li><li>\u2022 entry of lithium ions</li><li>\u2022 sodium channels in the collecting duct cells</li><li>\u2022 mitigating the diabetes insip</li><li>\u2022 lithium.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Desmopressin is effective for treating central diabetes insipidus because it acts on V2 receptors to mitigate the symptoms , but it does not work for nephrogenic diabetes insipidus , where the kidney is unresponsive to ADH .</li><li>\u27a4 Desmopressin</li><li>\u27a4 central diabetes insipidus</li><li>\u27a4 acts on V2 receptors</li><li>\u27a4 mitigate the symptoms</li><li>\u27a4 does not</li><li>\u27a4 nephrogenic diabetes insipidus</li><li>\u27a4 kidney is unresponsive to ADH</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "7750b70b",
      "audio": ""
    }
  ]
}